NIH_SPENDING_CATS: Behavioral and Social Science;Breast Cancer;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Dissemination and Implementation Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Prevention;Primary Health Care;Rehabilitation;Social Determinants of Health;Women's Health Research

ORG_CITY: HOUSTON

ORG_NAME: BAYLOR COLLEGE OF MEDICINE

PHR: PROJECT NARRATIVE Medically underserved patients have the highest burden of multiple chronic conditions and are at increased risk for poor outcomes during and after cancer treatment. As medically underserved complex cancer patients may lack healthcare knowledge and access to supportive care, their health outcomes and care transitions might be improved by enhancing communication and collaboration between their oncologists and primary care providers (PCPs). This study tests and evaluates a novel shared care model for complex cancer survivors called OPTIMISE that shifts the timing of thinking about survivorship to point of diagnosis and seeks to develop a clinical infrastructure to support continuity of care from cancer diagnosis through post-treatment survivorship.

PI_NAMEs: BADR, HODA J. (contact);MIMS, MARTHA P

PROJECT_TERMS: Accident and Emergency department;active method;Address;Adherence;Adoption;Affect;Aftercare;Area;Attitude;Baseline Surveys;breast cancer diagnosis;cancer care;cancer diagnosis;Cancer Patient;cancer risk;Cancer Survivor;Cancer Survivorship;cancer therapy;care coordination;care systems;Caring;Chronic;chronic care model;Chronic Disease;Clinic Visits;clinical care;clinical infrastructure;clinical practice;Clinics and Hospitals;Collaborations;collaborative care;Communication;comorbidity;Complex;Comprehensive Health Care;Continuity of Patient Care;Data;Diagnosis;Disease Management;Disease-Free Survival;ethnic minority;experience;Face;Feedback;follow-up;Future;Goals;Guidelines;Health;health care service utilization;Healthcare;Healthcare Systems;Hematologic Neoplasms;implementation outcomes;improved;Individual;Interruption;Interview;Knowledge;Late Effects;Life Style Modification;Low income;Malignant Breast Neoplasm;Malignant neoplasm of gastrointestinal tract;Malignant Neoplasms;Medical;medical specialties;medically underserved;Methods;Modeling;Monitoring for Recurrence;multiple chronic conditions;Newly Diagnosed;novel;Nurses;Oncologist;Oncology;Oncology Nurse;Outcome;Outcome Assessment;Pathway interactions;patient subsets;Patients;prevent;Preventive care;Primary Care;primary care provider;primary outcome;Process;Protocols documentation;Provider;provider communication;Psychosocial Assessment and Care;Public Hospitals;Qualitative Evaluations;Quality of life;racial minority;Randomized;Randomized, Controlled Trials;Reach, Effectiveness, Adoption, Implementation, and Maintenance;Recurrence;Reporting;Research;Resource-limited setting;Risk;risk stratification;safety net;scale up;Second Primary Cancers;secondary outcome;Self Management;Structure;Supportive care;Surveillance Modeling;survivorship;System;Testing;Thinking;Time;Translations;trend;Uninsured;uptake;Visit

PROJECT_TITLE: OPTIMISE: A Shared Care Approach for Improving Comprehensive Care of Cancer Patients with Comorbidities in A Safety-Net System


ADMINISTERING_IC: CA

ARRA_FUNDED: N

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Behavioral and Social Science;Cancer;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Hematology;Orphan Drug;Patient Safety;Pediatric;Pediatric Cancer;Prevention;Rare Diseases

ORG_CITY: BUFFALO

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

ORG_NAME: ROSWELL PARK CANCER INSTITUTE CORP

ORG_STATE: NY

PHR: Public Health Significance Recent landmark studies from the Children’s Oncology Group (COG) highlight adherence to home-based oral chemotherapy as an enduring problem in pediatric cancer care. Yet, little is known about why some families have difficulty adhering to their child’s home-based oral chemotherapy while others do not. Through the novel examination of how behavioral parenting skills shape adherence at the episode and daily levels the proposed program of research has potential to lead to a paradigm shift in pediatric cancer adherence risk prediction and interventions, moving away from blunt demographic-based risk prediction and identifying behavioral parenting skills that are easily amenable to screening, modifiable, and may be more precise predictors of non-adherence risk.

PI_NAMEs: BOUCHARD, ELIZABETH  (contact)

PROGRAM_OFFICER_NAME: FERRER, REBECCA

PROJECT_TERMS: Acute Lymphocytic Leukemia;Adherence;Age;Behavior assessment;behavior measurement;Behavioral;Biological Markers;biomarker validation;cancer care;Cancer Relapse;cancer risk;caregiving;Cause of Death;Cessation of life;chemotherapy;Child;Child Behavior;Child health care;Child Rearing;Childhood;Classification;clinical care;clinically significant;Code;Conflict (Psychology);Data;Data Collection;Deglutition;diaries;Disease;Dose;Drops;Drug Prescriptions;Education;Educational process of instructing;efficacy evaluation;Electronics;Enrollment;Ensure;Equation;experience;Family;Goals;Health Care Costs;health disparity;Home;Hospitalization;improved;Ingestion;innovation;Intervention;Learning;Life;Malignant Childhood Neoplasm;Malignant Neoplasms;Measurement;Measures;Medical;medication administration;medication compliance;Medication Management;medication nonadherence;Medicine;Methodology;Methods;Modeling;Monitor;Morbidity - disease rate;mortality;novel;Nurses;Oral;Parents;Participant;Patient Self-Report;Patients;Pediatric Oncology Group;Pediatrics;Pharmaceutical Preparations;pharmacologic;pill;Procedures;programs;Public Health;Randomized, Controlled Trials;recruit;Research;Resistance;restraint;retention rate;Risk;risk prediction;satisfaction;Schedule;Scheme;screening;secondary outcome;Shapes;side effect;skills;Specific qualifier value;Stress;Surveys;Techniques;Testing;Time;translational impact;treatment as usual;Treatment Failure;Treatment outcome;United States National Institutes of Health;usability

PROJECT_TITLE: Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence

STUDY_SECTION: CMGC

STUDY_SECTION_NAME: Clinical Management in General Care Settings Study Section[CMGC]


NIH_SPENDING_CATS: Cancer;Infectious Diseases;Orphan Drug;Rare Diseases

ORG_CITY: PHILADELPHIA

ORG_NAME: WISTAR INSTITUTE

ORG_STATE: PA

PHR: Project Narrative EBV-associated cancers represent an important unmet medical need. New therapeutic strategies are required to improve patient outcomes. We have developed small molecules inhibitors to EBNA1 to treat EBV latent infection driving EBV-associated cancers. We now propose to better understand how tumor cells respond to these inhibitors and enhance their efficacy by rational combinatorial therapies and structure-based chemical modifications.

PI_NAMEs: MESSICK, TROY E (contact)

PROGRAM_OFFICER_NAME: AGYIN, JOSEPH KOFI

PROJECT_TERMS: Animal Model;anticancer activity;Antineoplastic Agents;Apoptosis;Automobile Driving;Basic Science;Binding;cancer therapy;cancer type;carcinogenesis;cell growth;Cell model;Cell Proliferation;Cell Survival;cell type;Chemicals;chemotherapeutic agent;chemotherapy;Cisplatin;Clustered Regularly Interspaced Short Palindromic Repeats;combinatorial;Data;Development;Disease;DNA Binding;DNA Binding Domain;Drug Design;efficacy evaluation;Elements;endonuclease;Epstein-Barr Virus latency;Epstein-Barr Virus-Related Malignant Neoplasm;Fluorouracil;Foundations;Gene Expression;Generations;Genetic;Genome;Goals;Growth;Human;Human Herpesvirus 4;immune checkpoint;Immune checkpoint inhibitor;immune function;improved;in vivo evaluation;inhibitor;insight;Investigation;latent infection;Latent virus infection phase;Ligands;Malignant Neoplasms;Mediating;Medical;Medicine;Modeling;Modification;Molecular;multicatalytic endopeptidase complex;Mus;neoplastic cell;next generation;novel therapeutic intervention;novel therapeutics;Nuclear Antigens;Nuclear Protein;Oncogenic Viruses;Pathway interactions;patient derived xenograft model;Patient-Focused Outcomes;Pharmaceutical Preparations;Pharmacogenomics;programs;Property;Radiation;Recording of previous events;recruit;Reporting;Resolvase;response;Site;small hairpin RNA;small molecule;small molecule inhibitor;small molecule therapeutics;standard of care;Structure;synergism;targeted agent;Testing;Therapeutic;Therapeutic Agents;transcriptomics;Translational Research;Treatment Efficacy;tumor;tumor growth;tumorigenesis;Ubiquitin;ubiquitin-protein ligase;Viral;Viral Genes;Viral Genome;Viral Proteins;Virus;Work

PROJECT_TITLE: Drugging EBNA1 to Treat EBV-Associated Cancers

STUDY_SECTION: DMP

STUDY_SECTION_NAME: Drug Discovery and Molecular Pharmacology Study Section[DMP]


ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

NIH_SPENDING_CATS: Behavioral and Social Science;Breast Cancer;Cancer;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Racial and Ethnic Minority Health Research;Rural Health;Social Determinants of Health;Women's Health Research

ORG_CITY: ATLANTA

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: EMORY UNIVERSITY

ORG_STATE: GA

PHR: PROJECT NARRATIVE Breast cancer mortality disparities remains an important public health and clinical challenge. Understanding breast cancer recurrence is a critical target in reducing disparities, but a lack of population-based data limit inferences. The proposed study will advance our understanding of multi-level drivers of demographic disparities in recurrence and breast cancer-specific mortality, and facilitate prioritization of intervention targets.

PI_NAMEs: MCCULLOUGH, LAUREN E (contact)

PROGRAM_OFFICER_NAME: CRONIN, KATHLEEN A

PROJECT_TERMS: Accounting;Adopted;Affect;Area;Black Populations;Black race;breast cancer diagnosis;Breast Cancer Patient;Breast Cancer survivor;cancer health disparity;Cancer Prognosis;cancer recurrence;cancer survival;Caring;Cells;Censuses;Characteristics;Clinical;Clinical Data;Clinical Research;Communities;Data;data registry;data streams;Death Rate;demographic disparity;demographics;Diagnosis;Disease;Disparate;Disparity;disparity reduction;Distal;Distant;Early Diagnosis;economic disparity;Epidemiologic Methods;ethnic disparity;Ethnic Origin;Event;evidence base;experience;Funding Opportunities;Guidelines;high risk;Hospitals;improved;Individual;Inequity;innovation;Institution;intersectionality;Intervention;Investigation;lifetime risk;Low income;low socioeconomic status;Malignant Breast Neoplasm;Mediating;Mediator;Minority;mortality;mortality disparity;multidisciplinary;multilevel analysis;neoplasm registry;Nonmetastatic;Not Hispanic or Latino;Outcome;outcome disparities;Outcomes Research;Pathway interactions;Pattern;Policies;Population;population based;Population Heterogeneity;Population-Based Registry;Positioning Attribute;Prevalence;Prognosis;Public Health;Race;racial determinant;racial disparity;Recurrence;Research;Risk Estimate;Role;Rural;rural disparities;rural residence;Social Environment;social epidemiology;Societies;Source;Statistical Methods;survival disparity;Survivors;Time;Tumor Biology;United States;Woman;women's diagnosis;Women's mortality;Work

PROJECT_TITLE: Improving our understanding of breast cancer mortality disparities through recurrence: a multi-level approach among women in Georgia

STUDY_SECTION: CHSA

STUDY_SECTION_NAME: Cancer, Heart, and Sleep Epidemiology A Study Section[CHSA]


ED_INST_TYPE: SCHOOLS OF MEDICINE

NIH_SPENDING_CATS: Aging;Cancer;Genetics;Ovarian Cancer;Prevention;Rare Diseases;Women's Health Research

ORG_CITY: SEATTLE

ORG_DEPT: PATHOLOGY

ORG_NAME: UNIVERSITY OF WASHINGTON

ORG_STATE: WA

PHR: NARRATIVE The biological mechanisms that drive genetic susceptibility to ovarian cancer are not well understood. This grant will use ultra-sensitive sequencing to characterize with high resolution TP53 mutations in fallopian tube during normal aging and in women with susceptibility to ovarian cancer to determine whether elevated risk of ovarian cancer is associated with increased somatic TP53 clonal evolution. This research will increase our understanding of ovarian carcinogenesis and enable to develop better strategies for ovarian cancer prevention and prediction.

PI_NAMEs: RISQUES, ROSA ANA  (contact)

PROGRAM_OFFICER_NAME: LI, JERRY

PROJECT_TERMS: Age;age difference;Aging;Autopsy;Biological;Biopsy;Blood;BRCA1 gene;BRCA1 Mutation;cancer genetics;carcinogenesis;Cells;Centenarian;Clonal Evolution;Clonal Expansion;Clonality;Clustered Regularly Interspaced Short Palindromic Repeats;Collecting Tube;Constitution;Coupled;Data;Detection;Disease;Distal;DNA;driver mutation;Early Diagnosis;early screening;Environmental Risk Factor;Evaluation;Excision;Frequencies;Gene Order;General Population;Genetic Predisposition to Disease;Genetic Risk;Germ Lines;Germ-Line Mutation;Goals;Grant;Gynecologic;high risk;High Risk Woman;Histologic;Human;improved;Incidence;Incidental Findings;Knowledge;Lesion;Life;life span;lifetime risk;Location;Malignant neoplasm of ovary;Malignant Neoplasms;Mammalian Oviducts;Methods;mutant;Mutation;mutation carrier;Natural History;Nature;neoplastic;Newborn Infant;normal aging;Normal tissue morphology;novel;Operative Surgical Procedures;Organ;Ovarian;ovarian cancer prevention;Ovary;overexpression;Pap smear;Pathogenesis;Pathogenicity;Pathologic;Peritoneal Fluid;Peritoneum;Population Process;Positioning Attribute;Predisposition;prevent;Process;prophylactic;Proteins;Recommendation;Reporting;repository;Research;Resolution;Risk;Risk Reduction;risk variant;Role;Salpingo-Oophorectomy;Sampling;Serous;Site;Testing;Tissues;TP53 gene;trait;tumorigenesis;Woman

PROJECT_TITLE: Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer

STUDY_SECTION: CG

STUDY_SECTION_NAME: Cancer Genetics Study Section[CG]


NIH_SPENDING_CATS: Cancer;Clinical Research;Colorectal Cancer;Digestive Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Stem Cell Research - Nonembryonic - Non-Human

ORG_CITY: PORTLAND

ORG_DEPT: ANATOMY/CELL BIOLOGY

ORG_NAME: OREGON HEALTH & SCIENCE UNIVERSITY

ORG_STATE: OR

PHR: Metastatic disease accounts for >90% of cancer-related deaths worldwide, yet this phase of tumor progression is the least biologically understood. To address this challenge, we will integrate newly developed protein phenotyping technology, sophisticated computational biologic analyses, and an understudied neoplastic hybrid cell that represents the largest tumor population in peripheral blood. Our proposed study will explore the biology underlying the lifecycle of a disseminated neoplastic hybrid cells providing new insights into metastatic disease effectors, identification of pre-metastatic tumor states, and evaluation of a stage II colorectal cancer patient cohort in need of new approaches for treatment stratification to impact their survival.

PI_NAMEs: GIBBS, SUMMER LYNNE;WONG, MELISSA H. (contact)

PROGRAM_OFFICER_NAME: WATSON, JOANNA M

PROJECT_TERMS: Address;Aggressive behavior;Architecture;Area;Behavioral;Binding Sites;Biological;Biological Assay;Biology;Blood specimen;cancer care;Cancer Etiology;Cells;Cellular biology;Cessation of life;Circulation;Clinical;cohort;colon cancer patients;Colorectal Cancer;Computer Analysis;Copy Number Polymorphism;Development;Diagnosis;Disease;Disseminated Malignant Neoplasm;Distant;DNA Sequence Alteration;Effector Cell;Elements;Evaluation;Evolution;fluorescence imaging;Foundations;Gene Expression;Human;Hybrid Cells;Hybrids;Immunofluorescence Immunologic;in vivo;Incidence;innovation;insight;Investigation;Knowledge;Life Cycle Stages;Link;Location;longitudinal analysis;Malignant Neoplasms;Mediating;metastatic process;Micrometastasis;migration;Molecular;multidisciplinary;multiple omics;Nature;Neoplasm Circulating Cells;Neoplasm Metastasis;neoplastic;neoplastic cell;novel;novel therapeutic intervention;Outcome;Patient Care;Patients;Periodicity;peripheral blood;Phase;Phenotype;Population;Primary Neoplasm;Property;Prospective Studies;protein expression;Proteins;Publishing;Recurrence;Recurrent tumor;Reporting;Risk;Role;Sampling;Site;Spatial Distribution;stem cells;stemness;Technology;technology development;Testing;Therapeutic;Time;treatment response;treatment stratification;tumor;Tumor Biology;tumor growth;tumor initiation;tumor progression;Tumor stage;Work;Zebrafish

PROJECT_TITLE: Mechanistic understanding of the lifecycle of a circulating hybrid cell

STUDY_SECTION: TPM

STUDY_SECTION_NAME: Tumor Progression and Metastasis Study Section[TPM]


ED_INST_TYPE: BIOMED ENGR/COL ENGR/ENGR STA

NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Clinical Research;Ovarian Cancer;Prevention;Rare Diseases;Women's Health Research

ORG_CITY: TUCSON

ORG_DEPT: BIOMEDICAL ENGINEERING

ORG_NAME: UNIVERSITY OF ARIZONA

ORG_STATE: AZ

PHR: NARRATIVE There is currently no acceptable screening method for ovarian cancer, and most cases are detected when the disease is widespread and likely to be deadly. We will develop a two-step blood-based biomarker followed by a minimally-invasive fallopian tube imaging and sampling technique, as an effective method to detect ovarian cancer at an early time when the disease is most curable.

PI_NAMEs: BARTON, JENNIFER KEHLET (contact);FISHMAN, DAVID A.;LOKSHIN, ANNA E.

PROGRAM_OFFICER_NAME: MARQUEZ, GUILLERMO

PROJECT_TERMS: Algorithms;Bilateral;Biological Markers;biomarker validation;Blinded;Blood;Blood Proteins;Blood Screening;Blood specimen;Blood Tests;blood-based biomarker;CA-125 Antigen;Cancer Etiology;Cancerous;Carcinoma;Carcinoma in Situ;cell preparation;Cells;classification algorithm;Clinical;clinically actionable;Collecting Cell;Collection;Data;Detection;Development;Diagnosis;Disease;Early Detection Research Network;Early Diagnosis;Endoscopes;Endoscopy;Epithelial Cells;Epithelial ovarian cancer;Epithelium;Family;Fertility;fluorescence imaging;Genetic;Goals;Greater sac of peritoneum;Health;high resolution imaging;High Risk Woman;Histology;Human;Hysterectomy;Image;Image Analysis;imaging biomarker;Imaging Techniques;improved;in vitro Model;in vivo;Instruction;Lead;Lesion;Malignant neoplasm of ovary;Malignant Neoplasms;Mammalian Oviducts;Metastatic Malignant Neoplasm to the Ovary;Methods;miniaturize;minimally invasive;Morbidity - disease rate;mortality;Neoplasm Metastasis;Operative Surgical Procedures;optical imaging;Ovarian;Ovarian Serous Adenocarcinoma;Ovary;Patients;Pilot Projects;Predictive Value;premalignant;Procedures;protein biomarkers;Proteomics;prototype;Recommendation;Recording of previous events;Research;Resolution;Risk;Risk Reduction;Salpingo-Oophorectomy;Sampling;screening;Screening for Ovarian Cancer;Sensitivity and Specificity;Serous;Serum;Serum Markers;Serum Proteins;spectrograph;Survival Rate;Symptoms;System;Target Populations;Techniques;Technology;Test Result;Testing;Thinness;Time;Tissues;Transvaginal Ultrasound;Woman;Women's mortality;Women's study;Work

PROJECT_TITLE: Ovarian Cancer Detection with Blood- and Imaging-Based Biomarkers


NIH_SPENDING_CATS: Breast Cancer;Cancer;Immunotherapy;Women's Health Research

ORG_CITY: RICHMOND

ORG_DEPT: PHARMACOLOGY

ORG_NAME: VIRGINIA COMMONWEALTH UNIVERSITY

ORG_STATE: VA

PHR: Narrative Statement This project is designed to evaluate the capacity of senolytic agents to eliminate breast tumor cells induced into senescence by chemotherapy and radiation, with studies in both cell culture and tumor bearing animals, and to identify the contribution(s) of the immune system to the effectiveness of this therapeutic strategy.

PI_NAMEs: GEWIRTZ, DAVID A. (contact);HARADA, HISASHI ;LANDRY, JOSEPH WILLIAM

PROGRAM_OFFICER_NAME: VENKATACHALAM, SUNDARESAN

PROJECT_TERMS: Aftercare;Animals;anti-tumor immune response;Antigens;Antitumor Response;Apoptotic;assault;BCL1 Oncogene;BCL2L1 gene;Breast Cancer Cell;Breast Cancer Model;Breast Cancer Patient;cancer recurrence;Cell Culture Techniques;Cell Death;cell growth;Cell Survival;Cells;Characteristics;chemotherapy;Chemotherapy and/or radiation;Clinic;Clinical Trials;Cross Presentation;Cytolysis;Data;defined contribution;design;Disease;Dose;drug sensitivity;Effectiveness;Experimental Designs;experimental study;Exposure to;Goals;Growth;Human;Immune;Immune response;Immune system;immunogenic;immunogenic cell death;Immunologic Stimulation;In Vitro;in vitro Model;in vivo;Induction of Apoptosis;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;Mediating;Modeling;Monitor;mortality;mouse model;Mus;Natural Killer Cells;Nature;neoplastic cell;novel;Outcome Study;Patients;Phenotype;Population;pre-clinical;preclinical study;prevent;Property;Protein Family;Protocols documentation;Radiation;Radiation Tolerance;Recovery;Recurrent disease;Residual Neoplasm;Residual state;response;Role;Sampling;self-renewal;senescence;senescent cell;senolytics;Sequential Treatment;Series;Site;Sorting;Stable Disease;Stains;T-Lymphocyte;Testing;Therapeutic;Therapeutic Agents;therapeutic effectiveness;Time;Toxic effect;translational goal;Treatment Protocols;treatment response;tumor;Tumor Immunity;Tumor-infiltrating immune cells;Work;Xenograft procedure

PROJECT_TITLE: A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 1 Study Section[MCT1]


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Neurosciences;Orphan Drug;Precision Medicine;Prevention;Radiation Oncology;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Stem Cell Research - Nonembryonic - Non-Human

ORG_CITY: LOS ANGELES

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_NAME: UNIVERSITY OF CALIFORNIA LOS ANGELES

ORG_STATE: CA

PHR: Project Narrative This proposal will study novel combination therapies against glioblastoma. It targets a pathway glioma cells use to escape radiotherapy and aims to uncover novel ways to improve the efficacy of radiation treatment for glioblastoma patients.

PI_NAMEs: PAJONK, FRANK  (contact)

PROGRAM_OFFICER_NAME: FORRY, SUZANNE L

PROJECT_TERMS: 3-Dimensional;Affect;Basic Science;Biological Assay;Biological Markers;Biology;biomarker identification;biomarker validation;blood-brain barrier crossing;cancer cell;cancer stem cell;Cancer Therapy Evaluation Program;Cell Differentiation process;Cells;chemotherapeutic agent;Cholesterol;cholesterol biosynthesis;Clinical;Clinical Trials;Clonal Evolution;Combination Drug Therapy;Combined Modality Therapy;Data;Disease;disorder control;Dose;drug development;Drug Interactions;Drug Kinetics;effective therapy;Electromagnetic Energy;Fatty Acids;Gene Expression Profiling;Generations;Glioblastoma;Glioma;Goals;Hypoxia;imaging system;improved;In Vitro;in vivo;induced pluripotent stem cell;inhibitor;innovation;Level of Evidence;Literature;Malignant Breast Neoplasm;Malignant neoplasm of brain;Malignant Neoplasms;Metabolic;mevalonate;Modality;Modeling;mouse model;neoplastic cell;nerve stem cell;nestin protein;neurogenesis;Nitric Oxide;novel;Pathway interactions;patient derived xenograft model;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Phenotype;Population;prevent;Process;Publishing;Radiation;Radiation Dose Unit;Radiation Oncology;radiation resistance;Radiation therapy;radioresistant;Recurrence;Reporting;Resources;responders and non-responders;Scheme;self-renewal;Specimen;standard of care;stem cells;Surgical Oncology;synergism;targeted agent;targeted treatment;temozolomide;Testing;therapy outcome;therapy resistant;Time;tool;Toxic effect;trait;Transgenic Mice;Treatment Failure;tumor;tumor initiation;United States National Institutes of Health

PROJECT_TITLE: Use of CTEP portfolio compounds to counteract phenotype conversion in GBM

STUDY_SECTION: RTB

STUDY_SECTION_NAME: Radiation Therapeutics and Biology Study Section[RTB]


NIH_SPENDING_CATS: Behavioral and Social Science;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Dissemination and Implementation Research;HIV/AIDS;Infectious Diseases;Lung;Lung Cancer;Prevention;Substance Misuse;Tobacco;Tobacco Smoke and Health

ORG_CITY: CHARLESTON

ORG_NAME: MEDICAL UNIVERSITY OF SOUTH CAROLINA

ORG_STATE: SC

PHR: PROJECT NARRATIVE Despite the promise of smoking cessation interventions in people living with HIV (PLWH), intervention potential is limited by a lack of understanding about how to best implement evidence-based cessation strategies in this population. Tobacco treatment with first-line pharmacotherapy, delivered remotely in a proactive, opt-out fashion presents an opportunity for PLWH to receive robust, evidence-based tobacco treatment even if they are not currently motivated to quit smoking. By optimizing the delivery of effective tobacco treatments for PLWH, we hope to increase the number of people receiving tobacco treatment, increase tobacco cessation rates, and reduce the risk of morbidity and mortality from smoking-related causes.

PI_NAMEs: ROJEWSKI, ALANA  (contact)

PROGRAM_OFFICER_NAME: KAUFMAN, ANNETTE R

PROJECT_TERMS: Abstinence;Acquired Immunodeficiency Syndrome;Agreement;antiretroviral therapy;Area;Behavioral;Belief;Biochemical;Cancer Etiology;Caring;CD4 Lymphocyte Count;Cessation of life;Client satisfaction;Clinic;clinical care;Clinical Pathways;Communicable Diseases;Complex;Counseling;Country;Dissemination and Implementation;Effectiveness;effectiveness/implementation trial;Evaluation;evidence base;Evidence based intervention;follow-up;Future;future implementation;health care settings;Healthcare Systems;HIV;Hour;implementation evaluation;implementation facilitators;implementation fidelity;implementation outcomes;implementation process;implementation strategy;Incidence;Intervention;intervention delivery;Knowledge;Mail Order;Malignant neoplasm of lung;Measures;Medical;Methods;Morbidity - disease rate;mortality;motivational enhancement therapy;novel strategies;Outcome;outreach;Participant;Patient Compliance;patient engagement;patient population;Patients;Persons;Pharmaceutical Preparations;pharmacologic;Pharmacotherapy;Population;Prevalence;prevent;Provider;randomized, clinical trials;remote delivery;Research;Risk Reduction;Safety;Smoke;Smoker;Smoking;smoking cessation;Smoking Cessation Intervention;Smoking Status;Specialist;success;systemic barrier;Tobacco;Tobacco use;Tobacco Use Cessation;Training;treatment as usual;treatment comparison;United States;uptake;varenicline;Viral Load result;Visit;Writing

PROJECT_TITLE: Optimizing Tobacco Treatment Delivery for People Living with HIV


NIH_SPENDING_CATS: Biotechnology;Cancer;Immunotherapy

ORG_CITY: Columbus

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: OHIO STATE UNIVERSITY

ORG_STATE: OH

PHR: PROJECT NARRATIVE This study addresses how a chaperone molecule called GRP94 controls cancer and determines the best strategy to target GRP94 for cancer immunotherapy. Significant discoveries have been made regarding the roles of GRP94 in controlling the pathway of transforming growth factor beta (TGFb). Several therapeutic leads have emerged in blocking the GRP94-TGFb pathway; further in-depth study of GRP94 will advance novel therapies for cancer.

PI_NAMEs: LI, ZIHAI  (contact)

PROGRAM_OFFICER_NAME: HU, ZHANG-ZHI

PROJECT_TERMS: Address;anti-cancer;Antibodies;Area;B-Lymphocytes;Binding;Biochemical;Biogenesis;Biology;Blood Platelets;Cancer Biology;cancer cell;Cancer Control;cancer immunotherapeutics;cancer immunotherapy;cancer therapy;cell growth;Cell surface;cell type;chimeric antigen receptor;Client;Clinical;Clinical Trials;Collaborations;Complex;convict;Degradation Pathway;design;Development;Docking;effector T cell;Endoplasmic Reticulum;engineered T cells;Eragrostis;Foundations;genetic approach;Goals;Growth Factor Receptors;GRP94;Heat-Shock Proteins 90;Human;Immune;immune checkpoint;Immune checkpoint inhibitor;immune resistance;Immune Tolerance;Immunity;Immunologics;Immunotherapeutic agent;Immunotherapy;inhibitor;insight;Insulin-Like Growth Factor I;Insulin-Like Growth Factor II;Integrins;Laboratories;leucine-rich repeat protein;LRRC32 gene;Malignant Neoplasms;Manuscripts;Mediating;Membrane Glycoproteins;migration;Molecular;Molecular Chaperones;Myelogenous;Nature;new therapeutic target;next generation;novel;novel therapeutics;Oncogenic;overexpression;paralogous gene;Pathway interactions;PD-1/PD-L1;Pharmaceutical Preparations;Phase;Play;pre-clinical;Pre-Clinical Model;preclinical study;protein degradation;Proteins;Publishing;Quality Control;receptor;Regulation;Regulatory T-Lymphocyte;Renaissance;Resistance;response;Role;side effect;Signal Pathway;Signal Transduction;Structural Biologist;Suppressor-Effector T-Lymphocytes;Surface;T cell therapy;T-Lymphocyte;targeted treatment;Therapeutic;Thrombin;Transforming Growth Factor beta;Translational Research;Tumor Escape;tumor microenvironment;tumorigenesis;VWF gene

PROJECT_TITLE: Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy

STUDY_SECTION: CII

STUDY_SECTION_NAME: Cancer Immunopathology and Immunotherapy Study Section[CII]


ED_INST_TYPE: UNIVERSITY-WIDE

NIH_SPENDING_CATS: Cancer;Immunotherapy;Urologic Diseases

ORG_CITY: BRONX

ORG_NAME: ALBERT EINSTEIN COLLEGE OF MEDICINE

PHR: The proposed research is directly relevant to public health and NIH’s mission, because our program will result in new functional and mechanistic understanding of a new immune checkpoint pathway in human bladder cancer. This new insight will directly translate into novel immunotherapies for the treatment of human bladder cancer.

PI_NAMEs: ZANG, XINGXING  (contact)

PROJECT_TERMS: Acceleration;anti-PD-L1 antibodies;Basic Science;Biology;Bladder;cancer type;CD276 gene;CD28 gene;CD8-Positive T-Lymphocytes;CD80 gene;Cells;checkpoint inhibition;Clinical;Clinical Management;Clinical Research;combinatorial;Computational Biology;Coupled;CTLA4 gene;Cytoplasmic Tail;Data;Development;Disease;effective therapy;Endogenous Retroviruses;experience;Family;Family member;FDA approved;Future;Human;Human Biology;humanized mouse;Immune;immune checkpoint;Immune checkpoint inhibitor;Immunoglobulin Domain;Immunoglobulins;Immunologist;Immunosuppression;Immunotherapy;inhibitor;innovation;insight;ITIM;Killer Cells;Knowledge;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Mediating;Medical Oncology;member;Membrane;Mission;Modeling;Molecular;Monkeys;Monoclonal Antibodies;mouse model;multidisciplinary;Mus;Natural Killer Cells;new therapeutic target;novel;Oncologist;Outcome;overexpression;Pathway interactions;Patients;PD-1/PD-L1;PDL1 inhibitors;Phylogenetic Analysis;programmed cell death ligand 1;programmed cell death protein 1;programs;Public Health;Publishing;Qualifying;Rattus;Reagent;receptor;Recurrence;Research;Research Personnel;Resources;response;Signal Transduction;Survival Rate;System;Testing;therapeutic target;Translating;Translational Research;Treatment Efficacy;Trees;United States;United States National Institutes of Health;Urologist;Urology;VTCN1 gene;Work

PROJECT_TITLE: A New Immune Checkpoint Pathway in Human Bladder Cancer

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-OTC-D(08)F]


ADMINISTERING_IC: AR

IC_NAME: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

NIH_SPENDING_CATS: Back Pain;Chronic Pain;Clinical Research;Clinical Trials and Supportive Activities;Disability Research;Pain Research

ORG_DEPT: PHYSICAL MEDICINE & REHAB

PHR: Chronic low back pain is a major contributor to disability in the United States. Lumbar radiofrequency ablation (LRFA) is a non-surgical procedure to treat chronic low back pain. This randomized controlled trial will determine if conventional LRFA and a newer type of LRFA — multi-tined LRFA — are effective treatments for chronic low back pain.

PI_NAMEs: FRIEDLY, JANNA L;SURI, PRADEEP  (contact)

PROGRAM_OFFICER_NAME: WASHABAUGH, CHARLES H

PROJECT_TERMS: Ablation;Adverse effects;Anatomy;Anesthetics;arm;Back;Characteristics;Chronic low back pain;Clinical;Clinical effectiveness;clinical practice;comparative;compare effectiveness;comparison control;Control Groups;disability;Disability treatment;Double-Blind Method;effective therapy;Effectiveness;effectiveness evaluation;Electrodes;evidence based guidelines;Exposure to;Facet joint structure;Guidelines;Health Care Costs;improved;Intervention;Ionizing radiation;Lesion;Local Anesthetics;Low Back Pain;Measures;Medial;Medicare;Meta-Analysis;Methodology;minimally invasive;Mission;Modification;Multicenter Trials;Musculoskeletal;National Institute of Arthritis, and Musculoskeletal, and Skin Diseases;Nerve;new technology;Outcome;Outcome Study;Pain;Pain intensity;pain relief;Participant;Patient Selection;Patients;Policies;Procedures;Protocols documentation;Publishing;Questionnaires;Radiation Dose Unit;Radiofrequency Interstitial Ablation;Randomized;Randomized, Controlled Trials;Reporting;Research Support;response;screening;Selection Criteria;Societies;Specific qualifier value;Spinal;Structure;Techniques;treatment effect;Treatment Effectiveness;trial design;United States;Vertebral column;years lived with disability

PROJECT_TITLE: A Superiority Trial of Radiofrequency Ablation for Low Back Pain

STUDY_SECTION: AMSC

STUDY_SECTION_NAME: Arthritis and Musculoskeletal and Skin Diseases Clinical Trials Study Section [AMSC]


NIH_SPENDING_CATS: Biotechnology;Brain Cancer;Brain Disorders;Cancer;Genetics;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: COLUMBUS

ORG_NAME: RESEARCH INST NATIONWIDE CHILDREN'S HOSP

PHR: NARRATIVE MDM2 and its numerous isoforms are key regulators of the expression and function of the p53 gene, a critical tumor suppressor that prevents inappropriate cell growth and proliferation. The proposed research will study the molecular connection between DNA damage, MDM2 isoform switching, p53, and cancer. Unraveling this pathway could lead to the discovery of novel therapeutic intervention points and thus be a crucial stepping-stone for cancer drug discovery.

PI_NAMEs: CHANDLER, DAWN S (contact)

PROGRAM_OFFICER_NAME: MAAS, STEFAN

PROJECT_TERMS: Adult;Alanine Transaminase;Alternative Splicing;Antineoplastic Agents;Astrocytoma;Automobile Driving;Binding;Binding Proteins;Bioinformatics;Biological Assay;Biology;Biophysics;Breast;Cancer Biology;cancer therapy;cancer type;cell growth;Cell Line;Cell Proliferation;cell type;Cells;Cellular Stress;Chemistry;chemotherapeutic agent;Childhood Glioma;combinatorial;Complex;Coupled;Data;design;Disease;DNA Damage;Dominant-Negative Mutation;drug discovery;Engineering;Event;Excision;exon skipping;Exons;Future;gene-editing approach;Generations;Genetically Engineered Mouse;Genome;Genotoxic Stress;genotoxicity;Glioma;Goals;High-Throughput Nucleotide Sequencing;Human;In Vitro;industry partner;Knowledge;Length;liposarcoma;Lung;Lymphoma;Malignant Childhood Neoplasm;Malignant Neoplasms;MDM2 gene;Measures;Mechanics;Mediating;Methodology;Methods;MicroRNAs;Modality;Modeling;Molecular;mouse model;mRNA Precursor;Mus;Mutation;novel;novel therapeutic intervention;Nuclear;Nuclear Protein;Nuclear RNA;Oligonucleotides;Oncogenic;Outcome;Ovary;overexpression;Pathway interactions;Pharmacologic Substance;Phenotype;Play;Positioning Attribute;prevent;Primary Neoplasm;Property;Protein Isoforms;Proteins;Publishing;Regulation;Regulatory Element;Repression;Research;response;Rhabdomyosarcoma;RNA;RNA Biochemistry;RNA metabolism;RNA Processing;RNA Sequences;RNA Splicing;RNA-Binding Proteins;Role;Sampling;Stress;System;Technology;Testing;Therapeutic;Therapeutic Intervention;therapy design;TP53 gene;tumor;tumor progression;Tumor Suppressor Proteins;tumorigenesis;tumorigenic;Variant;Viral;Work;Xenograft procedure

PROJECT_TITLE: Mdm2 Alternative Splicing in DNA Damage and Cancer


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Infectious Diseases;Neurosciences;Orphan Drug;Rare Diseases

ORG_CITY: PROVIDENCE

ORG_NAME: BROWN UNIVERSITY

ORG_STATE: RI

PHR: Project Narrative Cytomegalovirus (CMV) is prevalent in humans and has been implicated in the malignant brain tumor glioblastoma (GBM) and other cancers. We have developed a novel murine model of CMV in GBM and identified for the first time potential molecular and cellular mechanisms by which CMV can accelerate tumor growth and alter responses to therapy. Therefore, in this project we will use this model alongside human GBM samples from patients with known CMV status to further understand the biology of CMV in GBM and assess new approaches to improve GBM treatment with the goal of rapid translation to the clinic.

PI_NAMEs: COOK, CHARLES H;LAWLER, SEAN EDWARD (contact)

PROGRAM_OFFICER_NAME: READ-CONNOLE, ELIZABETH LEE

PROJECT_TERMS: Acceleration;Address;Adjuvant Therapy;Affect;angiogenesis;Anti-viral Agents;Anti-viral Therapy;antiviral immunity;Area;Autologous Dendritic Cells;Automobile Driving;Biology;Biometry;blood vessel development;Blood Vessels;Brain Neoplasms;CD8-Positive T-Lymphocytes;chemoradiation;Chemosensitization;chemotherapy;Clinic;Clinical;Clinical Treatment;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;cooking;Cytomegalovirus;Cytomegalovirus Infections;Cytomegalovirus Vaccines;Data;Dedications;defined contribution;Diagnosis;differential expression;Disease;experience;experimental study;Future;Genes;Glioblastoma;Goals;Growth;Herpesviridae;Human;human data;Immune;Immunity;Immunocompetent;Immunoglobulin G;Immunology;Immunotherapy;Impairment;improved;improved outcome;in vivo;knock-down;Link;Malignant - descriptor;Malignant neoplasm of brain;Malignant Neoplasms;Mediating;Modeling;Molecular;mouse model;Mus;mutant;neoplastic cell;novel;novel strategies;Nucleic Acids;Operative Surgical Procedures;Outcome;Patient-Focused Outcomes;Patients;Pattern;Pericytes;Phenotype;Platelet-Derived Growth Factor;prevent;Primary Brain Neoplasms;Progression-Free Survivals;Proteins;Publishing;Radiation;recruit;Reporting;Research Personnel;Resistance;resistance mechanism;response;Role;Sampling;seropositive;standard of care;Survival Rate;Survivors;T cell infiltration;temozolomide;Therapeutic;therapeutic target;therapeutically effective;Time;transforming virus;Translations;Treatment outcome;treatment response;treatment strategy;tumor;tumor growth;tumor microenvironment;tumor progression;Up-Regulation;Valganciclovir;Viral;Virus;Virus Replication;YY1 Transcription Factor

PROJECT_TITLE: Defining the role of cytomegalovirus in glioblastoma therapies

STUDY_SECTION: CNBT

STUDY_SECTION_NAME: Clinical Neuroimmunology and Brain Tumors Study Section[CNBT]


NIH_SPENDING_CATS: Aging;Biomedical Imaging;Breast Cancer;Cancer;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Prevention;Racial and Ethnic Minority Health Research;Women's Health Research

ORG_CITY: HONOLULU

ORG_NAME: UNIVERSITY OF HAWAII AT MANOA

ORG_STATE: HI

PHR: PROJECT NARRATIVE The proposed studies are relevant to public health because they have the potential to identify women at high risk of breast cancer using ethnic-specific models. Thus, this advance is expected to have a high impact to the health and well being of women because women at high risk may choose to alter the breast cancer screening frequency for earlier detection or to participate in risk reduction strategies, such as lifestyle modification. Both approaches will reduce breast cancer mortality. This is relevant to the part of NIH's mission which focuses on the prevention of disease by supporting research in the prevention and early detection of human diseases.

PI_NAMEs: KERLIKOWSKE, KARLA M;SHEPHERD, JOHN ALAN (contact)

PROGRAM_OFFICER_NAME: CROSWELL, JENNIFER

PROJECT_TERMS: 3-Dimensional;Address;Adult;advanced breast cancer;Advanced Malignant Neoplasm;American Samoa;Artificial Intelligence;artificial intelligence model;Asian;Asian Americans;Asian population;Asian Women;Biological Markers;Black race;black women;Body mass index;Breast;Breast biopsy;Breast Cancer Detection;Breast Cancer Risk Factor;breast density;breast imaging;calcification;California;Cancer Center;cancer invasiveness;cancer risk;Characteristics;Chinese;Clinic;Clinical;clinical risk;Clinical Trials;cohort;Data;data registry;Databases;density;digital;disorder prevention;Early Diagnosis;Early treatment;ethnic difference;ethnic diversity;Ethnic Origin;Ethnic Population;experience;Family history of;Filipino;Frequencies;Goals;Guam;Hawaii;Health;high risk;High Risk Woman;Hispanic Women;human disease;Image;imaging biomarker;improved;improved outcome;Incidence;Japan;Japanese;Japanese American;Life Style Modification;Machine Learning;Malignant Breast Neoplasm;Malignant Neoplasms;Mammographic screening;Mammography;mammography registry;Measures;member;Mission;Modeling;Morbidity - disease rate;mortality;Native Hawaiian;Native Hawaiian or Other Pacific Islander;next generation;Not Hispanic or Latino;novel;Obesity;Pacific Islander;Pacific Islands;Pattern;Personal Satisfaction;Population;Population Heterogeneity;Population Study;Positioning Attribute;Prevalence;Prevention;programs;Public Health;racial difference;racial population;radiomics;Recording of previous events;Registries;reproductive;Research Personnel;Research Support;Resources;Risk;Risk Factors;risk prediction;Risk Reduction;Sampling;San Francisco;screening;Testing;Texture;tumor registry;United States National Institutes of Health;Universities;Weight Gain;White Women;Woman;women's morbidity;Women's mortality;women's outcomes

PROJECT_TITLE: Hawaii Pacific Islands Mammography Registry

STUDY_SECTION: CHSB

STUDY_SECTION_NAME: Cancer, Heart, and Sleep Epidemiology B Study Section[CHSB]


NIH_SPENDING_CATS: Cancer;Clinical Research;Neurosciences;Orphan Drug;Rare Diseases

ORG_CITY: SAN ANTONIO

ORG_NAME: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER

ORG_STATE: TX

PHR: To address “PQ9: What methods can be developed to effectively study small or rare populations relevant to cancer research” we will develop organoids of rare neuroendocrine tumors pheochromocytomas and paragangliomas (PPGL). Currently there are no markers of clinical behavior and malignant PPGLs can only be recognized after metastases develop, for which there are few treatment options. PPGL organoids will enable investigation of tumor markers of outcome and drug screen to identify potential new therapies.

PI_NAMEs: DAHIA, PATRICIA LEAL (contact);SORAGNI, ALICE

PROJECT_TERMS: Address;Adrenal Glands;Aggressive course;anti-cancer research;Area;Behavior;Biological;Biological Models;Biology;Catecholamines;CDK4 gene;Cells;chemotherapy;Clinical;clinical application;clinical heterogeneity;Clinical Management;clinical predictors;Clinical Trials;Data;design;Detection;Development;Diagnosis;Disease;drug candidate;Drug Screening;drug sensitivity;Early Diagnosis;effective therapy;Epithelium;Experimental Designs;Experimental Models;Future;Genetic;high-throughput drug screening;Human;improved;Individual;insight;Investigation;Knowledge;Low Prevalence;Malignant - descriptor;Malignant Neoplasms;Malignant Paraganglionic Neoplasm;Malignant Pheochromocytoma;Metastatic Pheochromocytoma;Methods;Modeling;Molecular;molecular marker;Morphologic artifacts;Neoplasm Metastasis;Nervous System;Neural Crest;neuroendocrine cancer;Neuroendocrine Tumors;novel;novel therapeutics;Organoids;Outcome;Paraganglia structure;Paraganglioma;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Pheochromocytoma;pluripotency;Population;predict clinical outcome;predictive marker;Primary Neoplasm;Property;Recurrence;Research;Resources;Survival Rate;targeted agent;Testing;Therapeutic;therapeutic evaluation;therapeutic target;transcriptome;tumor;tumor behavior;Tumor Biology;tumor initiation;Tumor Markers;tumor progression;whole genome

PROJECT_TITLE: Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model


NIH_SPENDING_CATS: Biotechnology;Cancer;Clinical Research;Emerging Infectious Diseases;HIV/AIDS;Immunization;Infectious Diseases;Rare Diseases

ORG_CITY: DUARTE

ORG_NAME: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE

PHR: PROJECT NARRATIVE Kaposi sarcoma-associated herpesvirus (KSHV) is the causal agent of Kaposi sarcoma, a common cancer in immunocompromised people (such as HIV/AIDS and transplant patients) and two lymphoid malignancies. We have designed a study to uncover the role of key KSHV glycoproteins in oral and systemic transmission of KSHV ex vivo and in vivo. We expect to generate critical data that will inform future design of an effective prophylactic KSHV vaccine candidate to prevent KSHV infection and its associated cancers.

PI_NAMEs: OGEMBO, JAVIER GORDON (contact)

PROJECT_TERMS: Africa;Age;Animal Model;Antibodies;Antibody-mediated protection;B-Lymphocytes;Binding;Body Fluids;Callithrix jacchus jacchus;Cell surface;cell type;Cells;Child;Collaborations;Complex;Data;design;Detection;Development;Disease;Endothelial Cells;Endothelium;Epithelial Cells;Epithelium;experimental study;Fibroblasts;Future;Glycoproteins;Goals;Herpesviridae;Herpesviridae Infections;HIV/AIDS;Human;Human body;Human Herpesvirus 8;human model;Iatrogenesis;Immunity;Immunize;Immunocompetent;Immunocompromised Host;immunodeficiency;immunosuppressed;Immunosuppression;In Vitro;in vivo;in vivo Model;Infection;Kaposi Sarcoma;Laboratories;latent infection;Lesion;Lymphocyte;Malignant lymphoid neoplasm;Malignant Neoplasms;Maternal antibody;Measures;Membrane;Modeling;Monoclonal Antibodies;mutant;nonhuman primate;novel;Oral;Oral cavity;oral infection;Pattern;permissiveness;Persons;polyclonal antibody;polyclonal human antibody;Predisposition;prevent;Preventive vaccine;Primary Infection;Primates;prophylactic;receptor;Receptor Cell;Recombinants;Reporting;Research;Risk;Role;Saliva;Sampling;Sexually Transmitted Diseases;Signal Transduction;Site;skin lesion;success;T-Lymphocyte;Testing;Tonsil;tool;transmission process;Transplant Recipients;Tropism;vaccine candidate;vaccine development;Viral;Viremia;Virion;Virus Diseases;Wisconsin;Work

PROJECT_TITLE: Unmasking the roles of viral glycoproteins in oral transmission of KSHV


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Cancer;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Hematology;Orphan Drug;Patient Safety;Pediatric;Pediatric Cancer;Racial and Ethnic Minority Health Research;Rare Diseases;Social Determinants of Health

ORG_CITY: MINNEAPOLIS

ORG_DEPT: PEDIATRICS

ORG_NAME: UNIVERSITY OF MINNESOTA

ORG_STATE: MN

PHR: Project Narrative Despite improvements in childhood cancer survival over the last several decades, marked racial, ethnic, and socioeconomic disparities in outcomes persist. Thus, understanding the socioeconomic factors contributing to disparities in relapse, toxicities, and survival may allow for intervention measures in the future.

PI_NAMEs: MARCOTTE, ERIN  (contact)

PROGRAM_OFFICER_NAME: GALLICCHIO, LISA M

PROJECT_TERMS: Acute Lymphocytic Leukemia;Address;Adolescent;Adverse event;adverse outcome;Area;Biological;Canada;cancer diagnosis;Cancer Patient;Cancer Relapse;cancer survival;cancer type;Caring;Censuses;Central Nervous System Neoplasms;Cephalic;Cessation of life;Child;Clinical Trials Cooperative Group;cohort;Collection;Common Terminology Criteria for Adverse Events;comorbidity;Cytogenetics;Data;Diagnosis;Disparity;economic determinant;Enrollment;ethnic disparity;Ethnic Origin;experience;Factor Analysis;Fever;follow-up;Future;Goals;hazard;Hispanic;Hospitals;improved;indexing;Infection;Institution;Insurance Coverage;International;Intervention;leukemia;Location;Logistic Regressions;low socioeconomic status;Lymphoma;Malignant Childhood Neoplasm;Malignant Neoplasms;Measures;Mediating;Mediation;Methods;Minnesota;Molecular;Morbidity - disease rate;mortality;Necrosis;Neoadjuvant Therapy;Neuropathy;Neutropenia;Not Hispanic or Latino;Odds Ratio;Outcome;outcome prediction;Outcome Study;Parents;participant enrollment;Pathway interactions;patient population;Patients;Pediatric Oncology Group;Population;Primary Neoplasm;Protocols documentation;Race;racial disparity;Recommendation;Registries;Relapse;relapse risk;Research;Research Personnel;Residual Neoplasm;Resources;Risk;Risk Reduction;risk stratification;Serious Adverse Event;sex;socioeconomic disparity;Socioeconomic Factors;Socioeconomic Status;socioeconomics;Solid Neoplasm;Standardization;Survival Rate;Survivors;survivorship;Therapeutic Trials;therapy outcome;Time;tool;Toxic effect;translational potential;Treatment-related toxicity;tumor;United States;Work

PROJECT_TITLE: Socioeconomic determinants of childhood cancer outcomes in a large contemporary cohort


NIH_SPENDING_CATS: Cancer;Childhood Leukemia;Clinical Research;Genetics;Hematology;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: NEW HAVEN

ORG_NAME: YALE UNIVERSITY

ORG_STATE: CT

PHR: Project Narrative: Despite enormous recent progress in treatment and supportive therapies for acute myeloid leukemia (AML), it accounts for the highest percentage of leukemic deaths, and less than a third of patients will become long-term survivors. We recently discovered that specific AML-associated mutations in two genes, isocitrate dehydrogenase-1 and -2 (IDH1/2), block DNA repair pathways and lead to sensitivity to drugs which block these same pathways. Here, we seek to develop highly effective combinations against AMLs with IDH1/2 mutations, as well as mutations in other AML-related genes.

PI_NAMEs: BINDRA, RANJIT  (contact);HALENE, STEPHANIE

PROGRAM_OFFICER_NAME: WITKIN, KEREN L

PROJECT_TERMS: Acute Myelocytic Leukemia;alpha ketoglutarate;Binding;Cessation of life;chemotherapy;Citric Acid Cycle;Clinic;Clinical Trials;Collection;Combined Modality Therapy;cytokine;Cytostatics;Data;Defect;Dioxygenases;DNA;DNA Damage;DNA Double Strand Break;DNA Repair Pathway;DNMT3a;Double Strand Break Repair;drug action;efficacy testing;Engineering;enzyme activity;Enzymes;Epigenetic Process;Event;FDA approved;FLT3 gene;Gene Mutation;Genes;hematopoietic differentiation;Heterozygote;Histones;homologous recombination;Hypermethylation;immunodeficiency;Impairment;In complete remission;In Vitro;in vivo;in vivo Model;Induced Mutation;inhibitor;insight;Isocitrate Dehydrogenase;Isocitrates;leukemia;leukemogenesis;Long-Term Survivors;Lysine;Malignant Neoplasms;Metabolic;Methylation;Mitogen-Activated Protein Kinases;Modeling;molecular subtypes;Mus;mutant;Mutation;Newly Diagnosed;novel therapeutic intervention;Pathway interactions;Patients;Pharmaceutical Preparations;Phenotype;Poly(ADP-ribose) Polymerase Inhibitor;Poly(ADP-ribose) Polymerases;Production;Protein Isoforms;Relapse;Reporting;Resistance;resistance mechanism;response;restoration;Signal Pathway;Signal Transduction;Site;Specimen;SRSF2 gene;Supportive care;synthetic lethal interaction;targeted treatment;Testing;Therapeutic;therapeutic target;therapy resistant;Toxic effect;Translating;Treatment Efficacy;Tricarboxylic Acids;tumor;Work;Xenograft Model

PROJECT_TITLE: Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML


NIH_SPENDING_CATS: Biomedical Imaging;Biotechnology;Cancer;Genetics;Immunotherapy;Lung;Lung Cancer;Orphan Drug;Rare Diseases

PHR: Project Narrative: The overarching goal of this study is to identify effective metabolic based diagnostic and therapeutic strategies to improve the overall survival of patients with Non-small cell lung cancer (NSCLC). We propose to investigate the positron emission tomography (PET) tracer, 18F-BnTP as a novel metabolic diagnostic and to develop metabolic based therapeutic strategies targeting oxidative mitochondrial metabolism in therapy resistant KRAS/LKB1 and EGFR mutant lung tumors. This work represents a new approach to overcoming therapy resistance in KRAS/LKB1 and EGFR mutant lung tumors – one in which the tumor’s metabolic and bioenergetic dependencies are profiled and then selectively targeted.

PI_NAMEs: SHACKELFORD, DAVID B (contact)

PROGRAM_OFFICER_NAME: WANG, YISONG

PROJECT_TERMS: 3-Dimensional;Address;advanced disease;American;Area;Biguanides;Bioenergetics;Biological Markers;Biopsy;Cancer Patient;cancer therapy;Cell Line;Cell Respiration;checkpoint therapy;Classification;Clinical;Complex;Data;Dependence;Diagnosis;Diagnostic;diagnostic strategy;Disease;Disease Resistance;Dissection;driver mutation;Electron Transport;Epidermal Growth Factor Receptor;Exhibits;fluorodeoxyglucose;Functional Imaging;Gene Expression Profiling;Genetically Engineered Mouse;Goals;Health;Human;image guided;imaging probe;Immuno-Chemotherapy;Immunotherapy;improved;in vivo;in vivo evaluation;in vivo imaging;inhibitor;Knowledge;KRAS2 gene;Lung Adenocarcinoma;Lung Neoplasms;Maintenance;Malignant neoplasm of lung;Measures;Membrane Potentials;Metabolic;Metabolic Pathway;metabolic profile;Metabolism;Mitochondria;mitochondrial membrane;mitochondrial metabolism;mutant;Mutation;nano-string;neoplastic cell;Non-Small-Cell Lung Carcinoma;novel;novel diagnostics;novel strategies;novel therapeutic intervention;novel therapeutics;Oncogenic;Oxidative Phosphorylation;patient derived xenograft model;Patients;Phenotype;Phosphorylation Inhibition;Physiological;Positron-Emission Tomography;Rationalization;Research;Resistance;Resistance development;Site;Spirometry;stem;STK11 gene;Structure;superresolution microscopy;Survival Rate;targeted treatment;Testing;Therapeutic;therapy development;therapy resistant;Time;Tracer;treatment response;tumor;tumor initiation;tumor metabolism;Tyrosine Kinase Inhibitor;uptake;Work

PROJECT_TITLE: In vivo imaging of mitochondria structure and function in therapy resistant lung tumors

STUDY_SECTION: IPCA

STUDY_SECTION_NAME: Imaging Probes and Contrast Agents Study Section[IPCA]


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Genetics;Hematology;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: NEW YORK

ORG_NAME: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

PHR: PROJECT NARRATIVE This proposed project aims to discover first-in-class small-molecule degraders of WDR5 as a novel therapeutic strategy for the treatment of MLL-rearranged leukemias. Currently, MLL-rearranged leukemia patients have a dismal prognosis and respond very poorly to standard treatments. Thus, the proposed research is directly relevant to public health.

PI_NAMEs: JIN, JIAN  (contact);WANG, G GREG

PROGRAM_OFFICER_NAME: O'HAYRE, MORGAN

PROJECT_TERMS: Acute leukemia;Acute Lymphocytic Leukemia;Acute Myelocytic Leukemia;antitumor effect;Apoptosis;Assessment tool;Binding;Biological Assay;biophysical properties;Biophysics;c-myc Genes;Cell Cycle Progression;cell killing;Cell model;Cell Proliferation;Cells;Chemicals;Childhood Leukemia;Chromatin;Clinic;Clinical Trials;Complex;design;Disease;Dose;drug candidate;Drug Kinetics;Drug Targeting;efficacy evaluation;Future;Gene Expression;Gene Expression Regulation;Genes;Genetic;Genetic Transcription;Growth;histone methyltransferase;Human;improved;In Vitro;in vivo;Infant;inhibitor;innovation;knock-down;Knock-out;Lead;leukemia;Leukemic Cell;Ligands;Link;Malignant Neoplasms;Mediating;Mixed-Lineage Leukemia;MLL gene;mouse model;novel therapeutic intervention;Oncogenic;Oncoproteins;patient derived xenograft model;Patients;pharmacologic;Prognosis;programs;Proliferating;Property;Protac;protein degradation;protein protein interaction;Public Health;recruit;Reporting;Research;Resolution;response;small molecule;small molecule inhibitor;standard care;Structure;targeted treatment;Technology;Tertiary Protein Structure;Testing;Therapeutic;therapeutic target;Toxic effect;transcriptome;Translating;treatment strategy;tumor growth;tumorigenesis;ubiquitin-protein ligase;Xenograft procedure

PROJECT_TITLE: Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias

STUDY_SECTION: DT

STUDY_SECTION_NAME: Developmental Therapeutics Study Section[DT]


ORG_CITY: HOUSTON

ORG_DEPT: BIOCHEMISTRY

ORG_NAME: BAYLOR COLLEGE OF MEDICINE

PHR: NARRATIVE  Cancer immunotherapies have achieved impressive clinical outcomes in a small subset of cancer patients. We will develop a novel therapeutic agent that can boost cancer immunotherapies. We expect that successful completion of this project will make a significant impact on cancer treatments.

PI_NAMEs: WANG, JIN  (contact)

PROGRAM_OFFICER_NAME: KONDAPAKA, SUDHIR B

PROJECT_TERMS: Accounting;Advanced Malignant Neoplasm;anti-PD-1;Antigens;Biological Assay;Biology;biomarker identification;cancer cell;Cancer cell line;cancer immunotherapy;Cancer Patient;cancer therapy;Canis familiaris;Cell Survival;Cells;Chemicals;Clinical;clinical translation;Complex;congenital immunodeficiency;Development;Dose;Drug Exposure;efficacy evaluation;Future;Genetic study;gut inflammation;Half-Life;Human;humanized mouse;Immune;immune checkpoint blockade;Immune system;Immunocompetent;Immunophenotyping;Immunotherapy;improved;in vivo;Individual;Induction of Apoptosis;Inflammatory;inhibitor;innate immune pathways;innovation;Interferons;Intervention;Investigation;Knock-out;Ligands;loss of function;Melanoma;meter;Modeling;Monkeys;Monoclonal Antibodies;mouse model;multiple omics;Mus;Mutation;novel therapeutics;Oral;Outcome;Pathway interactions;patient response;patient stratification;Patients;Pharmaceutical Chemistry;Pharmaceutical Preparations;pharmacologic;Pharmacology and Toxicology;Phenocopy;Phenotype;Phosphotransferases;Plasma;potential biomarker;Pre-Clinical Model;Property;Protac;Protein Kinase Interaction;Proteins;Proteome;Proteomics;Rattus;Receptor-Interacting Protein;recruit;Research;response;Scaffolding Protein;Signal Transduction;species difference;Specificity;success;Symptoms;synergism;T-Cell Activation;Technology;Testing;Therapeutic;Therapeutic Agents;TNF gene;Toll-like receptors;transcriptome;Transgenic Mice;Transgenic Organisms;triple-negative invasive breast carcinoma;tumor;tumor growth;Tumor Immunity;tumor initiation;tumor microenvironment;Variant;Work

PROJECT_TITLE: Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies


NIH_SPENDING_CATS: Aging;Cancer;Cancer Genomics;Genetics;Human Genome;Lung;Lung Cancer

ORG_CITY: PALO ALTO

ORG_NAME: PALO ALTO VETERANS INSTIT FOR RESEARCH

PHR: We propose to investigate novel mechanisms of action of the SIRT7 enzyme in regulating chromatin – the structure in which the human genome is packaged – and how these mechanisms are linked to mammalian aging and cancer biology. Defects in chromatin regulation can contribute to numerous aging-associated pathologies, including cancer, metabolic and neurodegenerative disease. This proposal will provide new insights into how chromatin mechanisms regulate important cellular functions, and has the potential to identify new targets for therapeutic intervention.

PI_NAMEs: CHUA, KATRIN F. (contact)

PROGRAM_OFFICER_NAME: OKANO, PAUL

PROJECT_TERMS: Acetylation;age related;Aging;aging mechanism;aging related;Attenuated;Automobile Driving;Biochemical;Biology;Biology of Aging;Cancer Biology;cancer cell;Cancer cell line;Cancer Etiology;Cell Aging;Cell Physiology;cell type;Cells;Cessation of life;Chemicals;Chromatin;chromatin modification;chromatin remodeling;Chromatin Structure;Coupled;Coupling;Deacetylase;Deacetylation;Defect;Disease;DNA;DNA Damage;DNA Methylation;Enzymes;Epigenetic Process;epigenomics;Event;Family;Gene Activation;Generations;Genetic Models;Genetic Transcription;Genome;Genomic Instability;genomic locus;Genomics;Goals;Histone Acetylation;Histone Deacetylation;Histone H3;histone modification;Histones;human cancer mouse model;Human Genome;in vivo;insight;KRAS2 gene;life span;Link;Longevity;Lung Adenocarcinoma;Lung Carcinoma;Lysine;Malignant - descriptor;Malignant Neoplasms;Mammalian Cell;Mammals;Mediating;Metabolic Diseases;Methylation;Modeling;Molecular;mouse model;Mus;Mutation;neoplastic;Nerve Degeneration;Neurodegenerative Disorders;new therapeutic target;Non-Small-Cell Lung Carcinoma;novel;Nuclear;Oncogenic;Oncoproteins;overexpression;Pathology;Pathway interactions;Phenocopy;Phenotype;pre-clinical;Premature aging syndrome;prevent;Process;programs;protective effect;Proteins;Regulation;Research;Resistance;response;restoration;Role;Saccharomycetales;senescence;Signal Pathway;Signal Transduction;Study models;Survival Rate;System;Testing;Therapeutic Intervention;Transact;tumor;tumorigenesis;United States;Work;Yeasts

PROJECT_TITLE: Histone Deacetylation Signaling in Aging and Cancer Pathways

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-OBT-J(02)M]


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Cancer Genomics;Genetics;Human Genome;Pediatric;Pediatric Cancer;Precision Medicine;Rare Diseases

ORG_CITY: ANN ARBOR

ORG_NAME: UNIVERSITY OF MICHIGAN AT ANN ARBOR

ORG_STATE: MI

PHR: Project Narrative This project entails the incorporation of new and emerging genomic, transcriptomic, and epigenomic technologies into cancer research and clinical testing programs. The generation and analyses of multiomic data in clinical cohorts of advanced, rare, and pediatric cancer cohorts is proposed. These advances in precision oncology will improve the discovery of actionable targets, diagnosis, and characterization of resistance mechanisms for cancer patients.

PI_NAMEs: ROBINSON, DAN RUSSEL (contact)

PROGRAM_OFFICER_NAME: OSSANDON, MIGUEL

PROJECT_TERMS: Acceleration;Advanced Malignant Neoplasm;analytical method;anti-cancer research;Area;bioinformatics pipeline;Biological Assay;Cancer Patient;Clinical;clinically actionable;cohort;Complement;Decision Making;Development;Diagnosis;Diagnostic;DNA;DNA methylation profiling;Emerging Technologies;epigenomics;Generations;Genomics;Goals;imprint;improved;Laboratories;Malignant Childhood Neoplasm;Malignant Neoplasms;Multiomic Data;multiple omics;Mutation;nanopore;new technology;novel strategies;Patients;precision oncology;prognostic;programs;promoter;Proteomics;rare cancer;Reporting;Research;research clinical testing;Resistance;resistance mechanism;Resources;RNA;Role;Sampling;Technology;Test Result;Therapeutic;transcriptomics;Translating;Translations;tumor;tumor DNA

PROJECT_TITLE: Integrative Multiomics and Clinical Laboratory Translation for Advanced, Rare, and Pediatric Cancers

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 SRB-1 (M2)]


ADMINISTERING_IC: ES

IC_NAME: NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Clinical Research;Depression;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Mental Health;Pediatric;Racial and Ethnic Minority Health Research;Social Determinants of Health

ORG_CITY: EAST LANSING

ORG_NAME: HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES

PHR: PROJECT NARRATIVE Extant work has only minimally considered the potential role of historical structural racism in shaping trajectories of neighborhood built, social, and toxicant conditions (the neighborhood exposome), nor has it considered how these historical conditions impact child mental health outcomes. The proposed study will be the first to evaluate historical patterns of structural racism in shaping the current and dynamic neighborhood exposome, and ultimately associations with child internalizing and externalizing behaviors, advancing both our understanding of the role of historical structural racism and neighborhood context in human development.

PI_NAMEs: BURT, S. ALEXANDRA ;PEARSON, AMBER L. (contact)

PROGRAM_OFFICER_NAME: GRAY, KIMBERLY A

PROJECT_TERMS: Accounting;Address;Air;Amendment;Anxiety;Attention deficit hyperactivity disorder;Black race;built environment;Characteristics;Child;Child Mental Health;Child Psychology;children of color;cohesion;community advisory board;conduct problem;Crime;dashboard;Data;Data Analytics;Data Collection;Data Set;Development;Economic Conditions;economic disparity;Environment;Environmental Health;Equity;externalizing behavior;Family;Fostering;geographic disparity;Geographic Information Systems;Geography;Goals;Grant;Green space;health disparity;Home;Housing;Human;Human Development;Imagery;improved;Investments;knowledge base;Leadership;Link;Literature;Location;Mental Depression;Mental Health;Michigan;Mind;Minority;Modernization;Motion;multi-racial;Nature;neighborhood disadvantage;Neighborhoods;Outcome;Pattern;population based;Prevalence;Race;racism;Recording of previous events;remediation;remote sensing;repaired;Research;Research Personnel;Resources;Role;rural area;Sampling;Science;sensor;Shapes;social;Social Conditions;Social Environment;Socioeconomic Status;socioeconomics;Soil;Source;Structural Racism;Surveys;Techniques;Time;toxicant;Toxin;urban area;virtual;Water;Work;Youth

PROJECT_TITLE: Illuminating the role of historical structural racism in the neighborhood exposome and modern-day child mental health

STUDY_SECTION: CIHB

STUDY_SECTION_NAME: Community Influences on Health Behavior Study Section[CIHB]


ADMINISTERING_IC: HL

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Brain Disorders;Cerebrovascular;Congenital Structural Anomalies;Genetics;Neurosciences;Pediatric;Stroke

ORG_CITY: CHARLOTTESVILLE

ORG_NAME: UNIVERSITY OF VIRGINIA

PHR: PROJECT NARRATIVE Brain arteriovenous malformations are abnormal connections between arteries and veins that result in a tangled network of blood vessels that are prone to rupture. Although they are the leading cause of stroke in children and young adults, the only available treatments are high-risk surgical approaches. We recently identified the genetic cause of the majority of brain arteriovenous malformations, and the goal of our project is to use our novel animal models of this disease to better understand bAVM pathogenesis and to use this information to develop drugs that can be used to treat it.

PI_NAMEs: FISH, JASON ;WYTHE, JOSHUA D. (contact)

PROGRAM_OFFICER_NAME: CHARETTE, MARC F

PROJECT_TERMS: Adult;Affect;Anatomy;Angiogenic Factor;Animal Disease Models;Animal Model;Arteries;Behavioral Assay;Biology;Blood capillaries;Blood flow;Blood Vessels;brain arteriovenous malformations;Brain hemorrhage;Brain Neoplasms;cadherin 5;cell behavior;Cell Culture Techniques;Cell Shape;Cells;Cellular biology;Central Nervous System;Cerebral cortex;Cessation of life;Child;Clinical;Cognition;Cognitive;Cues;Cultured Cells;Cytoskeleton;Data;design;Development;Diagnosis;Diameter;disability risk;Disease;Down-Regulation;Endothelial Cells;Endothelium;Etiology;Event;exome sequencing;Extracellular Matrix;Family history of;FDA approved;feeding;Frequencies;Functional impairment;Gene Expression;Gene Expression Profiling;Genes;Genetic;Genetic Transcription;Goals;GTP Binding;Guanosine Triphosphate Phosphohydrolases;hemodynamics;Hemorrhage;high risk;Histologic;Histology;Homeostasis;Human;Hypertension;Hypoxia;Image;Immunohistochemistry;improved;In Vitro;in vivo;inhibitor;insight;Intervention;Knowledge;KRAS2 gene;Label;Learning;Lesion;Maintenance;malformation;Medical;MEK inhibition;MEKs;Minority;Mitogen-Activated Protein Kinases;Modality;Modeling;Molecular;Molecular Target;Monomeric GTP-Binding Proteins;Morbidity - disease rate;Morphology;mosaic;Movement;Mus;mutant;Mutation;Neurofibrillary Tangles;neuron loss;novel;novel therapeutics;Operative Surgical Procedures;optogenetics;Pathogenesis;Pathologic;Pathway interactions;Patient-Focused Outcomes;Patients;Pericytes;Pharmaceutical Preparations;pharmacologic;Phenotype;Pre-Clinical Model;Predisposition;prevent;Process;Publishing;Radiation;recruit;Resistance;response;Risk;Rupture;Sampling;sensor;Severity of illness;shear stress;Shunt Device;Signal Transduction;single-cell RNA sequencing;Smooth Muscle Myocytes;Stress;Stroke;surgical risk;Testing;Therapeutic Embolization;therapeutic target;Time;transcriptomics;vascular bed;Vascular remodeling;Vascular Smooth Muscle;Veins;young adult;Zebrafish

PROJECT_TITLE: Decoding the Molecular and Cellular Mechanisms of Mutant KRAS-driven Brain Arteriovenous Malformations

STUDY_SECTION: BBHV

STUDY_SECTION_NAME: Basic Biology of Blood, Heart and Vasculature Study Section [BBHV]


NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Radiation Oncology

ORG_CITY: HANOVER

ORG_DEPT: ENGINEERING (ALL TYPES)

ORG_NAME: DARTMOUTH COLLEGE

ORG_STATE: NH

PHR: PROJECT NARRATIVE We propose to build an innovative, first-in-clinic, easy-to-use, oxygen scanner for repeated monitoring of tumor oxygen levels in cancer patients. The scanner will be built using the advanced in vivo electron paramagnetic resonance (EPR) technology developed at Dartmouth College and in partnership with ViewRay®, a pioneer in the development of MRI image-guided linear accelerator for radiation therapy. The new oxygen scanner can provide potentially important and previously unavailable information on tumor oxygen status, which is important for accurate prognosis and development of effective treatment strategies for cancer therapy.

PI_NAMEs: KUPPUSAMY, PERIANNAN  (contact)

PROGRAM_OFFICER_NAME: RIZWAN, ASIF M

PROJECT_TERMS: achievement test;Address;Animal Model;Automation;cancer care;Cancer Patient;cancer therapy;Clinic;Clinical;clinical care;Clinical Protocols;Clinical Research;clinical research site;cohort;college;commercialization;Computer software;Coupling;Custom;Data;data acquisition;Data Analyses;Data Collection;Data Reporting;Decision Making;design;design and construction;Development;Devices;diabetic;Diagnostic;digital;Documentation;effective therapy;efficacy evaluation;Electron Spin Resonance Spectroscopy;Engineering;ergonomics;Evaluation;flexibility;Generations;Good Manufacturing Process;Guidelines;healthy volunteer;heart motion;Human;human subject;image guided;image guided radiation therapy;improved;in vivo;industry partner;innovation;innovative technologies;instrumentation;light weight;Linear Accelerator Radiotherapy Systems;Magnetic Resonance Imaging;Malignant Neoplasms;manufacture;Marketing;Measurement;Measures;Medical Device;medical schools;Medical Technology;Monitor;Morphologic artifacts;Motivation;Movement;National Cancer Institute;novel;Oncology;operation;Oxygen;Oxygen saturation measurement;Patients;Performance;Peripheral Vascular Diseases;phantom model;Physiologic pulse;Prognosis;Program Research Project Grants;prototype;Radiation Oncology;Radiation therapy;Research;Resource-limited setting;Resources;respiratory;response;Role;Safety;safety and feasibility;Site;Speed;success;System;Technology;Testing;Therapeutic;therapy outcome;Time;tissue phantom;Tissues;tool;Translating;Treatment outcome;treatment strategy;tumor;Underserved Population;usability;user-friendly;Work

PROJECT_TITLE: EPR scanner for tumor oximetry in the clinic


NIH_SPENDING_CATS: Cancer;Clinical Research;Immunization;Immunotherapy;Infectious Diseases;Vaccine Related

PHR: PROJECT NARRATIVE T cells specific for previously encountered viruses are abundant in tissues throughout the body, including tumors, and can be leveraged for cancer immunotherapy. This proposal will further our understanding of how these cells function and develop novel strategies to enhance their efficacy. In doing so we will drive the translation of virus-specific T cell based immunotherapy toward clinical use.

PI_NAMEs: ROSATO, PAMELA  (contact)

PROGRAM_OFFICER_NAME: HARRIS, RAYMOND D

PROJECT_TERMS: 2019-nCoV;adaptive immune response;adaptive immunity;Address;anti-PD-L1;Automobile Driving;Blood Tests;cancer immunotherapy;CD8-Positive T-Lymphocytes;cell killing;Cell Physiology;Cells;Cellular immunotherapy;Clinic;Clinical;clinical translation;clinically significant;combinatorial;Complement;cytokine;Cytomegalovirus;Cytomegalovirus Infections;cytotoxic;Data;Detection;Development;Environment;Epstein-Barr Virus Infections;exhaustion;Functional disorder;Human;Human Herpesvirus 4;human model;Immune;immune checkpoint blockade;Immunologic Surveillance;Immunologics;Immunotherapy;in vivo;Infection;Inflammatory;Influenza A virus;influenza infection;innovation;Knowledge;Malignant Neoplasms;Melanoma;Melanoma patient;Melanoma Tumor;Memory;Messenger RNA;Methods;Modality;Modeling;mouse model;Mus;Natural Immunity;neoplasm immunotherapy;neoplastic cell;novel;novel strategies;pathogen;Patients;Peptides;Population;Predisposition;Production;programmed cell death ligand 1;recruit;Resistance;Slice;Solid Neoplasm;Specificity;Stains;System;T-Lymphocyte;targeted treatment;Testing;Therapeutic;tissue resident memory T cell;Tissues;translational therapeutics;Translations;Treatment Efficacy;tumor;Tumor Antigens;tumor growth;Tumor Immunity;Vaccines;Viral;Viral Antigens;Virus;Virus Diseases;Work

PROJECT_TITLE: Therapeutically harnessing anti-viral resident memory T cells in solid tumors


ED_INST_TYPE: HOSPITALS

NIH_SPENDING_CATS: Cancer;Digestive Diseases;Immunotherapy;Pancreatic Cancer;Rare Diseases

ORG_NAME: UNIVERSITY OF TX MD ANDERSON CAN CTR

PHR: PROJECT NARRATIVE Pancreatic ductal adenocarcinoma (PDAC) responds poorly to immunotherapy and the mechanisms of this resistance are unknown. We hypothesized that cancer-associated fibroblasts (CAFs) mediate this intratumoral immunosuppression in a HIF2-dependent fashion and provide evidence that HIF2 inhibition improves survival in mouse models of PDAC by potentially improving immune responses. In this grant, we explore the mechanisms of HIF2-dependent immune modulation by CAFs and perform preclinical studies to repurpose an FDA-approved HIF2 inhibitor to improve the response of pancreatic cancer to immunotherapy.

PI_NAMEs: TANIGUCHI, CULLEN MITSUO (contact)

PROGRAM_OFFICER_NAME: KUO, LILLIAN S

PROJECT_TERMS: Ablation;Animals;Biological Assay;blood perfusion;CD8B1 gene;Clinical;Clinical Research;clinical translation;Clinical Trials;Coculture Techniques;CRISPR/Cas technology;Data;Desmoplastic;effective therapy;Effector Cell;efficacy evaluation;Epithelium;Evaluation;FDA approved;Fibroblasts;Genetic Engineering;Genetic Transcription;Goals;Grant;Growth;Human;Hypoxia;hypoxia inducible factor 1;Immune;immune checkpoint blockade;Immune checkpoint inhibitor;Immune Evasion;Immune response;Immune system;Immune Targeting;Immunologics;immunomodulatory therapies;immunoregulation;Immunosuppression;Immunotherapy;improved;in vivo;inhibitor;innovation;Lymphocyte Activation;Macrophage;Macrophage Activation;Malignant neoplasm of pancreas;Malignant Neoplasms;Mass Spectrum Analysis;Mediating;Mediator;Metabolic;Methods;Modeling;Molecular;Molecular Target;mouse model;Mus;Nutrient;Outcome;Oxygen;Pancreas;pancreatic cancer cells;pancreatic cancer patients;Pancreatic Ductal Adenocarcinoma;pancreatic ductal adenocarcinoma model;pancreatic neoplasm;paracrine;paralogous gene;Pathway interactions;Patients;Pharmaceutical Preparations;Phenotype;pre-clinical;preclinical study;recombinase;Regulatory T-Lymphocyte;Renal Cell Carcinoma;Research;resistance mechanism;response;Role;Signal Transduction;spatiotemporal;T cell regulation;T-Cell Proliferation;T-Lymphocyte;Temperature;Therapeutic;therapy resistant;translational potential;Translations;tumor;tumor growth;tumor-immune system interactions;Work

PROJECT_TITLE: The Role of HIF2 in Pancreatic Ductal Adenocarcinoma


ED_INST_TYPE: SCHOOL OF MEDICINE & DENTISTRY

NIH_SPENDING_CATS: Breast Cancer;Cancer;Women's Health Research

ORG_CITY: ROCHESTER

ORG_DEPT: GENETICS

ORG_NAME: UNIVERSITY OF ROCHESTER

ORG_STATE: NY

PHR: Triple-negative breast cancer (TNBC) is an aggressive cancer subtype with limited treatment options. We have made the surprising discovery that the antioxidant glutathione (GSH) functions extracellularly, not intracellularly, to support TNBC growth. Our research will challenge the paradigm of antioxidant function in cancer by describing a novel mechanism of GSH function as a circulating source of amino acids and has the potential to reveal a completely new set of therapeutic targets for TNBC intervention.

PI_NAMEs: HARRIS, ISAAC SPENCER (contact)

PROGRAM_OFFICER_NAME: WILLIS, KRISTINE AMALEE

PROJECT_TERMS: Ablation;Affect;Amino Acids;antioxidant therapy;Antioxidants;Breast Cancer Cell;breast tumorigenesis;cancer cell;Cancer Intervention;cancer subtypes;cancer therapy;Catabolism;Cells;Cellular Metabolic Process;Cysteine;cysteinylglycine;Cystine;Data;deprivation;Dipeptidases;Dipeptides;experimental study;extracellular;Gamma-glutamyl transferase;Gatekeeping;Genetic;Glutamates;Glutathione;Glycine;Goals;Growth;In Vitro;in vivo;Intercellular Fluid;interest;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;Mediating;mouse model;new therapeutic target;novel;Outcome;Perception;Plasma;Plasma Cells;Proteins;Research;Role;Source;Supplementation;Testing;Therapeutic;therapeutic target;Tissues;triple-negative invasive breast carcinoma;tumor;tumor growth;tumor microenvironment;Tumor Promotion;tumorigenesis;Work

PROJECT_TITLE: Impact of extracellular glutathione catabolism on triple-negative breast cancer

STUDY_SECTION: TCB

STUDY_SECTION_NAME: Tumor Cell Biology Study Section[TCB]


NIH_SPENDING_CATS: Behavioral and Social Science;Breast Cancer;Cancer;Neurosciences;Sleep Research;Women's Health Research

ORG_CITY: Columbus

ORG_DEPT: PSYCHIATRY

ORG_NAME: OHIO STATE UNIVERSITY

PHR: PROJECT NARRATIVE The proposed research is relevant to public health because the elucidation of new mechanisms (i.e., chronobiology) will increase the understanding of the negative consequences of common drugs on brain and behavior. This mechanistic neuroscience cannot be done in humans. Thus, the proposed research is relevant to part of NCI/NIH’s mission that pertains to reducing cancer-related comorbidities, which in turn, improves health and quality of life.

PI_NAMEs: PYTER, LEAH M (contact)

PROGRAM_OFFICER_NAME: GOOD, MARGE

PROJECT_TERMS: Address;Adjuvant Chemotherapy;Affect;Alcohols;Anti-Inflammatory Agents;Basic Science;Behavior;Behavior assessment;behavior change;Behavioral;Biological;Biological Clocks;Biometry;Brain;Breast Cancer Patient;Breast Cancer survivor;Cancer Patient;cancer therapy;Cells;chemotherapy;Chemotherapy-Oncologic Procedure;Chronobiology;circadian;circadian biology;Circadian Dysregulation;circadian pacemaker;Circadian Rhythms;Clinical Data;clinical practice;Cognitive;comorbidity;Cues;Data;design;Diabetes Mellitus;disorder risk;Etiology;Eukaryota;experimental study;Fatigue;Foundations;Genes;Genetic;glial activation;Goals;hazard;Health;Health Benefit;Hospital Costs;Human;Hypothalamic structure;improved;in vivo;Inflammation;innovation;Intervention;Jet Lag Syndrome;Knowledge;Light;loved ones;Lupus;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;Medical Oncology;Mental Health;Methods;Mission;Molecular;mortality;Motivation;mouse model;neuroinflammation;Neurosciences;Nonpharmacologic Therapy;novel;Oncology;Operative Surgical Procedures;Outcome;Pacemakers;Paclitaxel;Pathway interactions;Patients;Periodicity;Pharmaceutical Preparations;pharmacologic;Phase;Phase response curves;Phototherapy;Physical assessment;Physiological;Physiology;Planning Techniques;Population;Predisposition;prevent;Psychoneuroimmunology;Public Health;Quality of life;Research;Research Project Grants;Resolution;Rest;Role;Running;Scientist;shift work;Signal Transduction;Stem cell transplant;suprachiasmatic nucleus;Survival Rate;Survivors;Symptoms;System;Systems Biology;Testing;translational model;United States National Institutes of Health;virtual;Work

PROJECT_TITLE: Chemotherapy-induced circadian master clock disruptions and fatigue

STUDY_SECTION: BNRS

STUDY_SECTION_NAME: Behavioral Neuroendocrinology, Neuroimmunology, Rhythms, and Sleep Study Section [BNRS]


ED_INST_TYPE: SCHOOLS OF NURSING

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Cancer;Cannabinoid Research;Chronic Pain;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Natural Products;Opioids;Pain Research;Palliative Care;Racial and Ethnic Minority Health Research;Social Determinants of Health;Substance Misuse;Therapeutic Cannabinoid Research

ORG_CITY: PHILADELPHIA

ORG_DEPT: OTHER HEALTH PROFESSIONS

ORG_NAME: UNIVERSITY OF PENNSYLVANIA

ORG_STATE: PA

PHR: PROJECT NARRATIVE Patients with cancer may use cannabis to manage symptoms, such as pain, and potentially reduce opioid use. Cannabis’ status as a Schedule 1 substance has made it difficult to study the role of cannabis use on pain and opioid use among cancer patients. This study will generate new knowledge to inform clinical practice and guidelines related to cannabis use in cancer pain and symptom management.

PI_NAMEs: ASHARE, REBECCA ;MEGHANI, SALIMAH H. (contact);WORSTER, BROOKE

PROGRAM_OFFICER_NAME: RISCUTA, GABRIELA

PROJECT_TERMS: Adjuvant Analgesic;Adult;African American;American;Anxiety;cancer health disparity;cancer pain;Cancer Pain Management;Cancer Patient;Cancer Science;cancer therapy;Cannabidiol;Cannabinoids;Cannabis;Cannabis policy;cannabis use behavior;Characteristics;Classification;Clinical;clinical practice;Clinical Practice Guideline;Cohort Studies;Cross-Sectional Studies;Data;Databases;design;District of Columbia;Ecological momentary assessment;Enrollment;Exhibits;falls;Female;Frequencies;Funding Agency;Guidelines;health disparity;Health system;Hydrocodone;improved;indexing;Inhalation;Interdisciplinary Study;interest;Knowledge;Laws;Malignant Neoplasms;Marijuana;marijuana legalization;marijuana use;marijuana user;Measures;Medical;Medical Marijuana;Medical Oncologist;Medicine;Methodology;National Cancer Institute;National Comprehensive Cancer Network;New England;Oncologist;Oncology;Opioid;opioid misuse;opioid therapy;opioid use;Oral;Outcome;Oxycodone;Pain;Pain management;pain outcome;Patient Outcomes Assessments;Patients;Pharmaceutical Preparations;pill;Plants;Practice Guidelines;prescription monitoring program;prescription opioid;Prospective cohort;Quality of life;Race;racial disparity;Recommendation;Reporting;Research;Research Design;Respondent;Role;Route;Sampling;Schedule;Science;Severities;side effect;Site;Sleep;Sleeplessness;Solid;Source;substance misuse;Surveys;symptom management;Telephone;Testing;Tetrahydrocannabinol;Time;tumor;United States;United States Food and Drug Administration;Work

PROJECT_TITLE: Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-HDM-A(90)]


NIH_SPENDING_CATS: Breast Cancer;Cancer;Genetics;Women's Health Research

PHR: Project Narrative: Poly(ADP)-ribose polymerase inhibitors (PARPi) exemplify a promising therapeutic strategy for the treatment of homology-repair deficient tumors. The proposed research is relevant to public health as elucidation of the cellular DNA repair mechanisms that respond to PARPi treatment will enable novel approaches to combat clinical issues of resistance and relapse. Successful completion of the proposed research will advance the NIH mission to improve human health by providing the framework for the development of new therapeutics for the treatment of BRCA and homology-repair deficient malignancies.

PI_NAMEs: JENSEN, RYAN BROWN (contact)

PROJECT_TERMS: Address;Agreement;Alleles;Binding;Biochemical;Biological;Biological Assay;brca gene;BRCA1 gene;BRCA2 gene;BRCA2 Mutation;Bypass;cancer cell;Cancer Patient;cancer therapy;Cell Death;Cell model;Cells;Cellular Assay;Clinical;Clinical Management;combat;Complex;Coupled;cytotoxicity;Data;Development;DNA;DNA Binding;DNA Damage;DNA fiber assay;DNA Repair;DNA replication fork;DNA Structure;Drug Design;drug sensitivity;EMSA;Event;Excision;Exhibits;FDA approved;Filament;Gene Mutation;gene repair;genome integrity;Germ-Line Mutation;Goals;Health;Human;improved;In Vitro;Individual;inhibitor therapy;innovation;insight;Invaded;Knowledge;Laboratories;Lesion;Malignant neoplasm of ovary;Malignant Neoplasms;Mediating;Mission;Modeling;Molecular;mutant;Mutation;novel;novel strategies;novel therapeutics;nuclease;Nucleoproteins;Pathogenicity;patient response;Patients;Play;Poly(ADP-ribose) Polymerase Inhibitor;Positioning Attribute;Process;protein purification;Proteins;Public Health;Reaction;reconstitution;recruit;Relapse;relapse patients;repair function;repaired;Research;Resistance;resistance mechanism;responders and non-responders;response;Role;single molecule;single-molecule FRET;Single-Stranded DNA;skills;superresolution microscopy;System;targeted treatment;Techniques;Testing;Therapeutic;therapy resistant;tool;Toxic effect;TRAP Complex;treatment strategy;tumor;United States National Institutes of Health;Work

PROJECT_TITLE: Defining the Roles of BRCA2 and RAD51 in PARPi Response

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 2 Study Section[MCT2]


ADMINISTERING_IC: AI

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

NIH_SPENDING_CATS: Bioengineering;Biotechnology;Clinical Research;Infant Mortality;Infectious Diseases;Microbiome;Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Prevention;Rare Diseases;Sexually Transmitted Infections;Women's Health Research

ORG_CITY: AUSTIN

ORG_DEPT: OBSTETRICS & GYNECOLOGY

ORG_NAME: UNIVERSITY OF TEXAS AT AUSTIN

PHR: Project narrative In consultation with end users, we will develop a first-in-class, inexpensive, rapid, and reliable point-of-care nucleic acid diagnostic to enable accessible and rapid testing for congenital syphilis. To enable development of modern diagnostics for maternal syphilis, we will evaluate detectability of syphilis pathogen DNA and syphilis associated microbiome changes in maternal vaginal swabs. The proposed project will make a significant impact on congenital syphilis prevention because our team has in-depth expertise, validated diagnostic assay and device technologies, public health nexus with sexual health care, industry partnerships for commercialization, and the commitment to make healthcare universally accessible.

PI_NAMEs: BHADRA, SANCHITA  (contact);HUBACH, RANDOLPH D

PROGRAM_OFFICER_NAME: GLOCK, JONATHAN A

PROJECT_TERMS: Acceleration;Address;Adopted;Adult;adverse pregnancy outcome;Age;Age Years;Antibiotics;Award;Bacteria;Biological Assay;biomarker development;Blood;Caring;Characteristics;Clinic;Clinical;Collaborations;Color;commercialization;Complex;Congenital Abnormality;congenital infection;Congenital Syphilis;Consultations;cost;Data;design;Detection;Development;Devices;Diagnosis;Diagnostic;diagnostic algorithm;diagnostic assay;Diagnostic Equipment;Diagnostic tests;diagnostic value;disease transmission;DNA;DNA-Directed DNA Polymerase;Dryness;Early Diagnosis;Education;Engineering;Ensure;Environment;Epidemic;fetal infection;fighting;flu;Future;Genes;Goals;Healthcare;Human;Immunoassay;improved;industry partner;Infant;infant infection;Infrastructure;instrument;internal control;Interview;isothermal amplification;Knowledge;Lateral;Legal;Legal patent;manufacture;Mediating;Medical;Methods;microbiome;microbiome alteration;Microfluidics;Modernization;Molecular;molecular diagnostics;Morbidity - disease rate;Neonatal;Neonatal Mortality;Newborn Infant;novel;novel diagnostics;novel therapeutics;Nucleic Acid Amplification Tests;Nucleic Acids;Oligonucleotides;Outcome;pathogen;Pathogen detection;Patients;Penicillins;peripheral blood;point of care;point of care testing;Polymerase Chain Reaction;portability;Poverty;preference;Pregnancy;pregnant;Pregnant Women;prevent;Prevention;Provider;Public Health;rapid detection;rapid testing;Recording of previous events;reproductive;Reproductive system;Research;Ribosomal DNA;Saliva;Sampling;self testing;Sensitivity and Specificity;Sexual Health;Signal Transduction;social;Specificity;Specimen;Spottings;Swab;Syphilis;Syphilitic chancre;Technology;Testing;Time;translational diagnostics;Translational Research;Translations;Treponema pallidum subspecies pallidum;uptake;Urine;usability;Uterus;Vagina;vaginal fluid;Validation;Vertical Transmission;Woman

PROJECT_TITLE: A Triad Approach Towards Improved Diagnostics for Maternal and Congenital Syphilis

STUDY_SECTION_NAME: Special Emphasis Panel[ZAI1 FDS-M (M1)]


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Genetics;Human Genome;Prostate Cancer;Urologic Diseases

ORG_CITY: DAVIS

ORG_DEPT: UROLOGY

ORG_NAME: UNIVERSITY OF CALIFORNIA AT DAVIS

PHR: PROJECT NARRATIVE Increasing evidence showing that AKR1C3 and AR/ARv7 play important roles in promoting prostate cancer progression and resistance. We have developed a number of novel small molecules that function as dual inhibitors of AR/ARv7 and AKR1C3. This application is aimed to determine the efficacy, mechanisms of action, and safety of these small molecules and to develop as novel agents to treat advanced prostate cancer.

PI_NAMEs: GAO, ALLEN C. (contact);LI, PUI-KAI

PROJECT_TERMS: abiraterone;advanced prostate cancer;Androgen Antagonists;Androgen Receptor;Androgens;Androstenedione;Anti-androgen Therapy;ATAC-seq;Automobile Driving;Biological Availability;Cancer Patient;Castration;Cell Count;cell growth;Cell Line;Cells;ChIP-seq;Chromatin;Chronic;Clinical;clinical development;Computer Models;CWR22Rv1;Data;design;Development;Dose;Drug Kinetics;Drug resistance;efficacy evaluation;enzalutamide;enzyme activity;Enzymes;Family;functional genomics;Future;Genes;genome-wide;Genomic approach;Goals;Growth;improved;In Vitro;in vivo;in vivo Model;inhibitor;Laboratories;Legal patent;Libraries;member;Metabolism;neoplastic cell;novel;novel strategies;novel therapeutics;Oxidoreductase;Pathway interactions;patient derived xenograft model;Patients;Play;Production;prostate cancer progression;Receptor Signaling;Resistance;Role;Safety;Signal Transduction;small molecule;Structure;targeted treatment;Technology;Testing;Testosterone;therapy resistant;Toxic effect;transcriptome;transcriptome sequencing;Translating;Treatment outcome;treatment response;tumor;tumor growth;tumor microenvironment;tumor progression;Variant;VCaP;Xenograft procedure

PROJECT_TITLE: Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer


NIH_SPENDING_CATS: Behavioral and Social Science;Bioengineering;Cancer;Clinical Research;Health Services;Lung;Lung Cancer;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Patient Safety;Social Determinants of Health

PHR: NARRATIVE Cancer continues to rank as the second leading cause of death in the US. We propose to study how teamwork, specifically communication and information sharing among large numbers of healthcare professionals, impact their patients’ outcome.

PI_NAMEs: MA, KWAN-LIU ;SEWELL, DANIEL ;TU, SHIN-PING  (contact);ZHU, XI

PROGRAM_OFFICER_NAME: BRICK, RACHELLE SOPHIA

PROJECT_TERMS: Academy;Accident and Emergency department;Address;Affect;Aftercare;aging population;Algorithms;analytical tool;beneficiary;Breast;cancer care;cancer diagnosis;Cancer Patient;cancer therapy;care systems;Caregivers;Cause of Death;Cessation of life;Clinical;Cognition;Colorectal;Combined Modality Therapy;Communication;Communication difficulty;comorbidity;cost;Data;Decision Making;design;digital;Dimensions;Discipline;effectiveness evaluation;Electronic Health Record;Emergency department visit;Fast Healthcare Interoperability Resources;Focus Groups;Future;Goals;graph neural network;health care delivery;Health Professional;Healthcare;Hospitalization;improved;Information Management;information processing;innovation;interest;Intervention;Intervention Studies;Interview;Knowledge;Machine Learning;Malignant Neoplasms;Measures;Mediating;Medical;Medicare;Medicine;Methods;Modeling;mortality;National Cancer Institute;National Research Council;Non-Small-Cell Lung Carcinoma;novel;Outcome;Pathway Analysis;Patient Care;Patient-Centered Care;Patient-Focused Outcomes;Patients;Performance;Policies;Population;Positioning Attribute;prototype;Quality of Care;Recommendation;Reporting;Research;Risk Reduction;Role;Site;social health determinants;Social Network;Structure;System;Systems Theory;Technology;theories;time use;tool;Treatment Protocols;United States;Visual;Visualization;Work

PROJECT_TITLE: SMART Cancer Care Teams: Enhancing EHR Communication to Improve Interprofessional Teamwork

STUDY_SECTION: CDMA

STUDY_SECTION_NAME: Clinical Data Management and Analysis Study Section[CDMA]


ORG_NAME: WEILL MEDICAL COLL OF CORNELL UNIV

PHR: PROJECT NARRATIVE Cancer is major socio-economic problem in the United States, with annual estimates at 1.7 million new diagnoses, over 600,000 cancer-related deaths, and health care costs exceeding 125 billion dollars. The focus of this proposal is to develop novel approaches that modulate selective host-microbiota interactions to limit tumor progression and improve the efficacy of checkpoint inhibitors in colorectal cancer.

PI_NAMEs: SONNENBERG, GREGORY F (contact)

PROGRAM_OFFICER_NAME: HOWCROFT, THOMAS K

PROJECT_TERMS: adaptive immunity;Address;anti-PD1 therapy;Automobile Driving;beneficial microorganism;Cancer Model;cancer type;Cells;Cessation of life;checkpoint therapy;Colorectal Cancer;cytokine;Cytoprotection;Data;Evolution;exhaustion;Exhibits;experimental study;Failure;Frequencies;Functional disorder;Genomic Instability;gut inflammation;gut microbiota;Health;Health Care Costs;Histocompatibility Antigens Class II;Homeostasis;host microbiota;host-microbe interactions;Human;human model;immune checkpoint blockade;Immune checkpoint inhibitor;Immunity;Immunologics;Immunotherapy;Impairment;improved;Infection;Inflammation;Intervention;Intestines;Invaded;Knowledge;Lymphocyte;Lymphoid Cell;Malignant Neoplasms;Microbe;microbial;microbiota;microbiota composition;Molecular;mouse model;Mus;neoplasm immunotherapy;Newly Diagnosed;novel;novel strategies;novel therapeutic intervention;pathogen;Pathway interactions;phenotypic biomarker;Population;prevent;Publishing;Regulation;Resistance;response;Role;Seminal;Shapes;socioeconomics;success;T-Lymphocyte;Testing;Therapeutic;Therapeutic Intervention;therapeutic target;Tissues;transcription factor;Tumor Cell Invasion;Tumor Immunity;tumor microenvironment;tumor progression;Tumor Promotion;United States;Vaccination

PROJECT_TITLE: Innate lymphoid cell regulation of the host-microbiota interactions in cancer


ORG_CITY: BOSTON

ORG_NAME: BOSTON UNIVERSITY MEDICAL CAMPUS

ORG_STATE: MA

PHR: Unscheduled whole-genome doubling events give rise to genetically unstable polyploid cells that can promote disease. The aims of this proposal are designed to identify unique the genetic adaptations acquired by polyploid cells that enable their sustained proliferation and survival. Successful completion of these aims will provide significant insight into the genesis and evolution of whole genome-doubled cells in vivo, as well as reveal innovative therapeutic avenues to selectively kill pathological polyploid cells while sparing the normal cells that comprise human tissue.

PI_NAMEs: GANEM, NEIL J. (contact)

PROGRAM_OFFICER_NAME: WITKIN, KEREN L

PROJECT_TERMS: Affect;Aging;Animal Model;Animals;Area;Biological;Biological Models;Biology;cancer cell;Cell Line;Cell model;Cell Proliferation;Cell Survival;Cells;Cellular biology;Chromosome abnormality;Chromosomes;Computer Analysis;Computer Models;CRISPR-mediated transcriptional activation;Cues;Data;Defect;Dependence;design;Development;Diploid Cells;Diploidy;Disease;Epithelial Cells;Event;Evolution;Frequencies;Gene Amplification;Gene Deletion;Generations;Genes;Genetic;Genome;Genomics;Goals;Growth;Hepatocyte;Human;human disease;human tissue;Image;In Vitro;in vivo;Incidence;innovation;insight;Kinesin;Knockout Mice;Lethal Genes;Maintenance;Malignant Neoplasms;Methodology;Mitotic;mouse model;Mutation;Nature;neoplastic cell;new therapeutic target;Normal Cell;overexpression;Pathologic;Pathway interactions;Phenotype;Physiological;Play;Ploidies;Polyploid Cells;Polyploidy;Primary Neoplasm;Proliferating;Repression;Research;Role;Route;screening;small molecule inhibitor;Solid Neoplasm;Testing;Therapeutic;Tissues;Transgenic Mice;tumor;Tumor Subtype;tumorigenesis;Variant;Vertebrates;whole genome;Work

PROJECT_TITLE: Mechanisms of cell proliferation in whole-genome doubled cells

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-OBT-M(02)M]


ADMINISTERING_IC: AA

IC_NAME: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

NIH_SPENDING_CATS: Alcoholism, Alcohol Use and Health;Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Clinical Research;Neurosciences;Substance Misuse

PHR: PROJECT NARRATIVE Studies of hypothalamic-pituitary-adrenal (HPA) dysregulation in individuals with alcohol use disorder (AUD) are based solely on peripheral cortisol, and results are inconsistent and incomplete because we have not been able to study a marker of brain cortisol – forming a significant gap in the existing literature. Translating preclinical findings in the brain to human AUD is a critical next step in understanding HPA dysfunction in this population. This proposal will derive critical foundational information about HPA axis dysregulation in AUD at baseline by fully characterizing the availability of 11β-HSD1, a cortisol-regenerating enzyme, in the brain and peripheral cortisol levels and determine relationships to drinking behavior in people with AUD vs. healthy controls.

PI_NAMEs: VERPLAETSE, TERRIL L (contact)

PROGRAM_OFFICER_NAME: BALAKATHIRESAN, NAGARAJA SETHURAMAN

PROJECT_TERMS: addiction;Adrenal Glands;Age;Alcohol consumption;Alcohol dependence;alcohol exposure;alcohol response;alcohol use disorder;Alcohols;Amygdaloid structure;Anterior;Biosensor;Brain;Brain imaging;Brain region;Chronic;chronic alcohol ingestion;cingulate cortex;Clinical;Corticosterone;Cortisone;Data;drinking;drinking behavior;Ecological momentary assessment;Enzymes;Foundations;Functional disorder;Future;Glucocorticoid Receptor;Glucocorticoids;heart rate variability;Hippocampus;Hormones;Human;Hydrocortisone;Hydroxysteroid Dehydrogenases;Hypothalamic structure;hypothalamic-pituitary-adrenal axis;Individual;innovation;Knowledge;Link;Literature;Measures;Methods;NADH dehydrogenase (ubiquinone);Natural regeneration;novel;Participant;Peripheral;Persons;Pituitary Gland;Plasma;Population;Positron-Emission Tomography;pre-clinical;Prefrontal Cortex;radiotracer;receptor expression;recruit;Research;Rodent;Role;Salivary;Scanning;Severities;sex;Stress;System;Translating;wearable device;Work

PROJECT_TITLE: Characterizing brain-periphery cortisol dysregulation in AUD

STUDY_SECTION: NAL

STUDY_SECTION_NAME: Neurotoxicology and Alcohol Study Section[NAL]